Study of Magrolimab Combination Therapy in Patients With... | NCT04854499 | Trialant
NCT04854499
Sponsor
Gilead Sciences
Status
Terminated
Last Update Posted
Nov 19, 2025Actual
Enrollment
193Actual
Phase
Phase 2
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Magrolimab
Pembrolizumab
Docetaxel
5-FU
Cisplatin
Carboplatin
Zimberelimab
Countries
United States
Australia
Belgium
France
Germany
Hong Kong
Italy
Poland
Portugal
Spain
United Kingdom
Protocol Section
Identification Module
NCT ID
NCT04854499
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
GS-US-548-5916
Secondary IDs
ID
Type
Description
Link
2020-005708-20
Other Identifier
EudraCT Number
Brief Title
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
Official Title
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
Acronym
ELEVATE HNSCC
Organization
Gilead SciencesINDUSTRY
Status Module
Record Verification Date
Nov 2025
Overall Recruitment Status or Expanded Access Status
Terminated
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Sponsor decision to terminate study
Expanded Access Info
No
Start Date
Sep 7, 2021Actual
Primary Completion Date
Oct 2, 2024Actual
Completion Date
Oct 2, 2024Actual
First Submitted Date
Apr 19, 2021
First Submission Date that Met QC Criteria
Apr 19, 2021
First Posted Date
Apr 22, 2021Actual
Results Waived
Not provided
Results First Submitted Date
Sep 30, 2025
Results First Submitted that Met QC Criteria
Nov 6, 2025
Results First Posted Date
Nov 19, 2025Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Not provided
Certification/Extension First Submitted that Passed QC Review
Not provided
Certification/Extension First Posted Date
Not provided
Last Update Submitted Date
Nov 6, 2025
Last Update Posted Date
Nov 19, 2025Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
Gilead SciencesINDUSTRY
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
No
Is FDA Regulated Drug
Yes
Is FDA Regulated Device
No
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in participants with head and neck squamous cell carcinoma (HNSCC).
Participants with untreated metastatic or unresectable, locally recurrent head and neck squamous cell carcinoma (HNSCC) regardless of programmed cell death ligand 1 (PD-L1) status will receive the following:
magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses
pembrolizumab 200 mg on Day 1 of each cycle
5-fluorouracil (5-FU) 1000 mg/m^2/day Days 1-4 of each cycle (for up to 6 cycles)
platinum chemotherapy (cisplatin 100 mg/m^2 or carboplatin area under the concentration versus time curve (AUC) 5 per investigator choice (for up to 6 cycles)) Participants will continue treatment until unacceptable toxicity or disease progression, whichever occurs first, and will not change their magrolimab dose level after the recommended Phase 2 dose (RP2D) is determined. Each cycle is 21 days.
Drug: Magrolimab
Drug: Pembrolizumab
Drug: 5-FU
Drug: Cisplatin
Drug: Carboplatin
Safety Run-in Cohort 2, Magrolimab + Docetaxel
Experimental
Participants with locally advanced/metastatic HNSCC regardless of PD-L1 status who were previously treated with at least 1 and no more than 2 lines of prior systemic therapy will receive the following:
magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses
docetaxel 75 mg/m^2 on Day 1 of each cycle Participants will continue treatment until unacceptable toxicity or disease progression, whichever occurs first, and will not change their magrolimab dose level after the RP2D is determined. Each cycle is 21 days.
The pre-expansion safety run-in cohort may be conducted at the sponsor's discretion prior to the initiation of Phase 2 Cohort 2. Participants with untreated metastatic or unresectable, locally recurrent HNSCC with a PD-L1 combined positive score (CPS) ≥ 1 will receive magrolimab and pembrolizumab 200 mg on Day 1 of each cycle. Each cycle is 21 days.
Participants will continue treatment until unacceptable toxicity or disease progression, whichever occurs first, and will not change their magrolimab dose level after the RP2D is determined. Each cycle is 21 days.
Safety Run-in Cohorts 1 and 2: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0
A DLT was defined as any Grade 3 or higher hematologic toxicity or Grade 3 or higher nonhematologic toxicity that had worsened in severity from pretreatment baseline during the DLT assessment period and, in the opinion of the investigator, the AE was related to magrolimab and the relationship of the AE with the combination partner regimen can be ruled out.
First dose date up to 21 days
Safety Run-in Cohorts 1 and 2: Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point up to and including last dose date of study drug plus 30 days (or last dose date of zimberelimab plus 90 days) and prior to the day of initiation of subsequent anti-cancer therapy.
First dose date up to 73 weeks plus 30 days
Phase 2 Cohort 1, Arms A and B: Progression-free Survival (PFS)
PFS was defined as the time from the date of randomization until the earliest date of documented disease progression, as assessed by investigator assessment, or death from any cause, whichever occurred first. Progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Kaplan-Meier (KM) estimates were used in outcome measure analysis.
Up to 129 weeks
Phase 2 Cohort 3: Objective Response Rate (ORR)
ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) as measured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 as determined by investigator assessment. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Secondary Outcomes
Measure
Description
Time Frame
Safety Run-in Cohort 1 and 2, Phase 2 Cohort 1 Arm A and Phase 2 Cohort 3: Serum Concentration of Magrolimab
Day 8 1-Hour Postdose; Days 15, 22, 43: Predose; Day 43 1-Hour Postdose; Day 71 1-Hour Postdose; Days 85,127, 190,197, 211, 253 Predose; Day 253 1-Hour Postdose
Safety Run-in Cohort 1 and 2, Phase 2 Cohort 1 Arm A, C and Phase 2 Cohort 3: Percentage of Participants Who Developed Antidrug Antibodies (ADAs) to Magrolimab
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Key Inclusion Criteria:
Histologically or cytologically confirmed metastatic or locally recurrent HNSCC that is considered incurable by local therapies.
Safety Run-in Cohort 1 and Phase 2 Cohorts 1
Should not have had prior systemic therapy administered in the recurrent or metastatic setting.
Eligible primary tumor locations include oropharynx, oral cavity, hypopharynx, and larynx. Nasopharynx is not included.
HNSCC per protocol specified inclusion criteria regardless of PD-L1 status.
Safety Run-in Cohort 2 and Phase 2 Cohort 3
Histologically or cytologically confirmed locally advanced/mHNSCC regardless of PD-L1 status with at least 1 and no more than 2 lines of prior systemic anticancer therapy in the locally advanced/metastatic setting.
Key Exclusion Criteria:
Active central nervous system (CNS) disease (individuals with asymptomatic and stable, treated CNS lesions who have been off corticosteroids, radiation, or other CNS-directed therapy for at least 4 weeks are not considered active).
History of (noninfectious) pneumonitis that required steroids or current pneumonitis.
Progressive disease within 6 months of completion of curatively intended treatment for locally advanced/mHNSCC.
Safety Run-in Cohort 1, Pre-expansion Safety Run-in Cohort for Magrolimab + Pembrolizumab (if Applicable), and Phase 2 Cohorts 1 and 2
Prior treatment with any of the following:
Anti-programmed cell death protein 1 or anti-PD-L1 checkpoint inhibitors.
Anti-cytotoxic T-lymphocyte-associated protein 4 checkpoint inhibitors.
Safety Run-in Cohort 2 and Phase 2 Cohort 3
Prior treatment with a taxane.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Accepts Healthy Volunteers
No
Sex
All
Sex/Gender Based
Not provided
Sex/Gender Description
Not provided
Minimum Age
18 Years
Maximum Age
Not provided
Standard Ages
AdultOlder Adult
Study Population
Not provided
Sampling Method
Not provided
Contacts/Locations Module
Central Contacts
Not provided
Overall Officials
Name
Affiliation
Role
Gilead Study Director
Gilead Sciences
Study Director
Locations
Facility
Status
City
State
ZIP
Country
Contacts
Ironwood Cancer and Research Center
Chandler
Arizona
85224
United States
City of Hope
References Module
Citations
PubMed Identifier
Type
Citation
Retractions
Background
Colevas AD, Dinis J, Chin V, Costa DA, Park JJ, Fang B, et al. A Phase 2 Study of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (ELEVATE HNSCC) [Poster TPS6102]. American Society for Clinical Oncology (ASCO); 2023 June 2-6; Chicago, IL.
Background
Colevas AD, Dinis J, Chin V, Costa DA, Park JJ, Fang B, et al. A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (ELEVATE HNSCC) [Abstract]. American Society for Clinical Oncology (ASCO); 2023 June 2-6; Chicago, IL.
Background
Colevas AD, Kerrigan K, Chin V, Rainey N, Park J, Fang B, et al. Safety and Tolerability of Magrolimab Combination Therapy in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM-HNSCC) [Poster #675]. SITC: 38th Society for Immunotherapy of Cancer Annual Meeting; 2023 November 3-5, 2023; San Diego, CA.
Background
Colevas AD, Kerrigan K, Chin V, Rainey N, Park J, Fang B, et al. Safety and tolerability of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC) [Abstract]. SITC: 38th Society for Immunotherapy of Cancer Annual Meeting; 2023 November 3-5, 2023; San Diego, CA.
Participants were enrolled at study sites in Europe, North America and Asia Pacific. Optional Phase 2 Cohort 2 was never opened due to closure of the study.
Participants received magrolimab + pembrolizumab + platinum + 5 FU (5-fluorouracil) intravenous (IV) infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 73 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 73 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18.3 weeks (for carboplatin).
Participants with untreated metastatic or unresectable, locally recurrent HNSCC regardless of PD-L1 status will receive magrolimab at the recommended Phase 2 dose (RP2D) determined in the Safety run-in cohort
1, pembrolizumab 200 mg on Day 1 of each cycle, 5-FU 1000 mg/m^2/day Days 1-4 of each cycle, and platinum chemotherapy (cisplatin 100 mg/m^2 or carboplatin AUC 5 per investigator choice). Each cycle is 21 days. Magrolimab will be continued until loss of clinical benefit, unacceptable toxicity, or death.
Pembrolizumab therapy will be administered for up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first. 5-FU and platinum chemotherapy will be administered for up to 6 cycles or until loss of clinical benefit or unacceptable toxicity, whichever occurs first.
Participants with untreated metastatic or unresectable, locally recurrent HNSCC regardless of PD-L1 status will receive pembrolizumab 200 mg on Day 1 of each cycle, 5-FU 1000 mg/m^2/day Days 1-4 of each cycle, and platinum chemotherapy (cisplatin 100 mg/m^2 or carboplatin AUC 5 per investigator choice). Each cycle is 21 days.
Pembrolizumab therapy will be administered for up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first. 5-FU and platinum chemotherapy will be administered for up to 6 cycles or until loss of clinical benefit or unacceptable toxicity, whichever occurs first.
Participants with untreated metastatic or unresectable, locally recurrent HNSCC regardless of PD-L1 status will receive magrolimab at the recommended Phase 2 dose (RP2D) determined in the Safety run-in cohort 1, zimberelimab 360 mg on Day 1 of each cycle, 5- FU 1000 mg/m^2/day Days 1-4 of each cycle, and platinum chemotherapy (cisplatin 100 mg/m^2 or carboplatin AUC 5 per investigator choice). Each cycle is 21 days.
Magrolimab will be continued until loss of clinical benefit, unacceptable toxicity, or death. Zimberelimab therapy will be administered up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first. 5-FU and platinum chemotherapy will be administered for up to 6 cycles or until loss of clinical benefit or unacceptable toxicity, whichever occurs first.
Drug: Magrolimab
Drug: 5-FU
Drug: Cisplatin
Drug: Carboplatin
Drug: Zimberelimab
Phase 2 Cohort 2, Magrolimab + Pembrolizumab
Experimental
Participants with untreated metastatic or unresectable, locally recurrent HNSCC with a PD-L1 combined positive score (CPS) ≥ 1 will receive magrolimab at the RP2D determined in the Safety run-in cohort 1 and pembrolizumab 200 mg on Day 1 of each cycle. Each cycle is 21 days.
Magrolimab will be continued until loss of clinical benefit, unacceptable toxicity, or death. Pembrolizumab therapy will be administered for up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first.
Drug: Magrolimab
Drug: Pembrolizumab
Phase 2 Cohort 3, Magrolimab + Docetaxel
Experimental
Participants with locally advanced/metastatic HNSCC regardless of PD-L1 status who were previously treated with at least 1 and no more than 2 lines of prior systemic therapy will receive magrolimab at the RP2D determined in the Safety run-in cohort 2 and docetaxel 75 mg/m^2 on Day 1 of each cycle. Each cycle is 21 days.
Magrolimab and docetaxel will be continued until loss of clinical benefit, unacceptable toxicity, or death.
Up to end of treatment (up to approximately 73 weeks)
Phase 2 Cohort 1, Arms B and C: Progression-free Survival (PFS)
PFS was defined as the time from the date of randomization (Phase 2 Cohorts 1) or date of dose initiation (Phase 2 Cohorts 2 and 3) until the earliest date of documented disease progression as determined by investigator assessment per RECIST, version 1.1, or death from any cause, whichever occurs first. Disease progression is defined in OM#2. KM estimates were used in outcome measure analysis.
Up to 129 weeks
Phase 2 Cohort 1, Arms A, B and C: Objective Response Rate (ORR)
ORR was defined as the percentage of participants who achieved a CR or PR as determined by investigator assessment. CR and PR are defined in OM#3.
Up to 129 weeks
Phase 2 Cohort 3: Progression-free Survival (PFS)
PFS was defined as the time from the date of dose initiation (Phase 2 Cohort 3) until the earliest date of documented disease progression as determined by investigator assessment per RECIST, version 1.1, or death from any cause, whichever occurs first. Disease progression is defined in OM#2. KM estimates were used in outcome measure analysis
Up to 129 weeks
All Phase 2 Cohorts: Duration of Response (DOR)
DOR was defined as the time from first documentation of CR or PR to the earliest date of documented disease progression or death from any cause, whichever occurs first. Disease progression is defined in OM#2 and CR and PR are defined in OM#3.
Up to 129 weeks
All Phase 2 Cohorts: Overall Survival (OS)
OS was defined as the time from the date of randomization (Phase 2 Cohorts 1) or time from the date of dose initiation (Phase 2) to death from any cause. KM estimates were used in outcome measure analysis.
Up to 129 weeks
Phase 2 Cohorts: Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) Score
EORTC QLQ-C30 is a quality of life (QOL) questionnaire for cancer participants, that has 30 items. 5 functional scales (physical, role, emotional, cognitive, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, loss of appetite, constipation, diarrhea, and financial difficulties). Scoring of the QLQ-C30 was performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the participant), while higher scores on the symptom and single-item scales indicated a higher level of symptoms (i.e. a worse state of the participant).
Phase 2 Cohorts: Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life - Head and Neck Module (EORTC QLQ-H&N35)
The H&N35 is a 35-item questionnaire for participants with H&N cancer. It includes 7 multi-item scales that assess pain (4 items), swallowing (4 items), senses (2 items), speech (3 items), social eating (4 items), social contact (5 items), and sexuality (2 items). There are also 11 single items: teeth, opening mouth, dry mouth, sticky saliva, coughing, felt ill, pain killers, nutritional supplements, feeding tube, weight loss, weight gain. All symptoms scales, scores were transformed in range of 0 to 100, where higher scores indicated more severe symptoms. A negative change from Baseline indicated improvement.
Phase 2 Cohorts: Number of Participants With 5-level EuroQol 5 Dimensions Questionnaire (EQ-5D-5L) Score
EQ-5D-5L was an instrument for use as a measure of health outcome. The EQ-5D-5L consisted of 2 sections: EuroQoL (5 dimensions) (EQ-5D) descriptive system and the EuroQoL visual analogue scale (EQ-VAS). EQ-5D comprised the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension had 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Number of participants per category are reported.
Phase 2 Cohorts: Change From Baseline in the EuroQol Visual Analogue Scale (EQ-VAS) Score
The EQ-VAS recorded the participant's self-rated health on a vertical VAS, where the end points were labeled "the best health you can imagine" and "the worst health you can imagine." The EQ-VAS could be used as a quantitative measure of a health outcome that reflected the participant's own judgment. The EQ-VAS recorded the participant's self-rated health on a vertical VAS, with a score numbered from 0 to 100, where '100 meant the best health you can imagine' and '0 meant the worst health you can imagine".
Participants received magrolimab + pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 72 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 88 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 22 weeks for carboplatin and 23 weeks for cisplatin.
Participants received pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 70 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks for carboplatin and 18 weeks for cisplatin.
Participants received magrolimab + zimberelimab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 37 weeks; Zimberelimab 360 mg IV on Day 1 of every 21-day cycle for up to 40 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18 weeks for carboplatin and 16 weeks for cisplatin.
FG004
Safety Run-in Cohort 2: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 69 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 13 weeks.
FG005
Phase 2 Cohort 3: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 42 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 34 weeks.
FG0006 subjects
FG00152 subjects
FG00254 subjects
FG00332 subjects
FG0048 subjects
FG00541 subjects
COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
NOT COMPLETED
FG0006 subjects
FG00152 subjects
FG00254 subjects
FG00332 subjects
FG0048 subjects
FG00541 subjects
Type
Comment
Reasons
Study Terminated by Sponsor
FG0005 subjects
FG00127 subjects
FG00228 subjects
FG00319 subjects
FG0041 subjects
FG00510 subjects
Death
FG0001 subjects
FG00123 subjects
FG00221 subjects
FG0037 subjects
FG004
Investigator's Discretion
FG0000 subjects
FG0011 subjects
FG0023 subjects
FG0034 subjects
FG004
Withdrew Consent
FG0000 subjects
FG0011 subjects
FG0022 subjects
FG0032 subjects
FG004
Lost to Follow-up
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Safety Run-in Cohort 1, Safety Run-in Cohort 2 + Phase 2 Cohort 3: The Modified Intent-to-Treat (mITT) Analysis Set included all participants who took at least 1 dose of study drug. Phase 2 Cohort 1: Intent-to-treat (ITT) Analysis Set for Phase 2 Cohort 1 included all participants who were randomized in Phase 2 Cohort 1 of the study.
Participants received magrolimab + pembrolizumab + platinum + 5 FU (5-fluorouracil) intravenous (IV) infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 73 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 73 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18.3 weeks (for carboplatin).
Participants received magrolimab + pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 72 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 88 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 22 weeks for carboplatin and 23 weeks for cisplatin.
Participants received pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 70 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks for carboplatin and 18 weeks for cisplatin.
Participants received magrolimab + zimberelimab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 37 weeks; Zimberelimab 360 mg IV on Day 1 of every 21-day cycle for up to 40 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18 weeks for carboplatin and 16 weeks for cisplatin.
BG004
Safety Run-in Cohort 2: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 69 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 13 weeks.
BG005
Phase 2 Cohort 3: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 42 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 34 weeks.
BG006
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG0006
BG00152
BG00254
BG00332
BG0047
BG00541
BG006192
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Categorical
Count of Participants
Participants
No
Title
Denominators
Categories
Title
Measurements
<=18 years
BG0000
BG0010
BG0020
BG003
Age, Continuous
Mean
Standard Deviation
years
Title
Denominators
Categories
Title
Measurements
BG00069± 6.2
BG00161± 7.4
BG002
Sex: Female, Male
Count of Participants
Participants
No
Title
Denominators
Categories
Title
Measurements
Female
BG0000
BG0019
BG002
Ethnicity (NIH/OMB)
Count of Participants
Participants
No
Title
Denominators
Categories
Title
Measurements
Hispanic or Latino
BG0000
BG0012
BG002
Race (NIH/OMB)
Count of Participants
Participants
No
Title
Denominators
Categories
Title
Measurements
American Indian or Alaska Native
BG0000
BG0010
BG002
Region of Enrollment
Count of Participants
Participants
No
Title
Denominators
Categories
Belgium
Title
Measurements
BG0000
BG0013
BG002
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Safety Run-in Cohorts 1 and 2: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0
A DLT was defined as any Grade 3 or higher hematologic toxicity or Grade 3 or higher nonhematologic toxicity that had worsened in severity from pretreatment baseline during the DLT assessment period and, in the opinion of the investigator, the AE was related to magrolimab and the relationship of the AE with the combination partner regimen can be ruled out.
DLT Evaluable Analysis Set was defined as all participants in the safety run-in evaluations who meet either of the following criteria during the DLT assessment period: The participants experienced a DLT at any time after initiation of the first infusion of magrolimab. The participant didn't experience a DLT and completed at least 2 infusions of magrolimab and at least 1 dose of pembrolizumab, platinum, and 5-FU for Safety Run-in Cohort 1; at least 1 dose of docetaxel for Safety Run-in Cohort 2.
Participants received magrolimab + pembrolizumab + platinum + 5 FU (5-fluorouracil) intravenous (IV) infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 73 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 73 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18.3 weeks (for carboplatin).
OG001
Safety Run-in Cohort 2: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 69 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 13 weeks.
Units
Counts
Participants
OG0006
OG0016
Title
Denominators
Categories
Title
Measurements
OG0000
OG0010
Primary
Safety Run-in Cohorts 1 and 2: Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point up to and including last dose date of study drug plus 30 days (or last dose date of zimberelimab plus 90 days) and prior to the day of initiation of subsequent anti-cancer therapy.
Safety Run-in Cohorts 1 and 2: The Safety Analysis Set included all participants who took at least 1 dose of any study drug.
Participants received magrolimab + pembrolizumab + platinum + 5 FU (5-fluorouracil) intravenous (IV) infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 73 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 73 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18.3 weeks (for carboplatin).
OG001
Safety Run-in Cohort 2: Magrolimab + Docetaxel
Primary
Phase 2 Cohort 1, Arms A and B: Progression-free Survival (PFS)
PFS was defined as the time from the date of randomization until the earliest date of documented disease progression, as assessed by investigator assessment, or death from any cause, whichever occurred first. Progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Kaplan-Meier (KM) estimates were used in outcome measure analysis.
Participants in Phase 2 Cohort 1, Arms A and B in the ITT analysis set were analyzed.
Participants received magrolimab + pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 72 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 88 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 22 weeks for carboplatin and 23 weeks for cisplatin.
Primary
Phase 2 Cohort 3: Objective Response Rate (ORR)
ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) as measured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 as determined by investigator assessment. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Participants in Phase 2 Cohort 3 in the mITT Analysis Set with available data were analyzed.
Posted
Number
95% Confidence Interval
percentage of participants
Up to 129 weeks
ID
Title
Description
OG000
Phase 2 Cohort 3: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 42 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 34 weeks.
Units
Counts
Participants
Secondary
Safety Run-in Cohort 1 and 2, Phase 2 Cohort 1 Arm A and Phase 2 Cohort 3: Serum Concentration of Magrolimab
Participants in the Pharmacokinetic (PK) Analysis Set with available data were analyzed. The PK Analysis Set, defined as all participants who received any amount of magrolimab and have at least 1 evaluable post-treatment serum concentration of magrolimab, at the given timepoint were analyzed. Per pre-specified plan, the PK analysis set included participants from Safety Run-in Cohort 1 and 2, Phase 2 Cohort 1 Arm A and Phase 2 Cohort 3.
Posted
Mean
Standard Deviation
μg/mL
Day 8 1-Hour Postdose; Days 15, 22, 43: Predose; Day 43 1-Hour Postdose; Day 71 1-Hour Postdose; Days 85,127, 190,197, 211, 253 Predose; Day 253 1-Hour Postdose
Participants received magrolimab + pembrolizumab + platinum + 5 FU (5-fluorouracil) intravenous (IV) infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 73 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 73 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18.3 weeks (for carboplatin).
Safety Run-in Cohort 1 and 2, Phase 2 Cohort 1 Arm A, C and Phase 2 Cohort 3: Percentage of Participants Who Developed Antidrug Antibodies (ADAs) to Magrolimab
Participants in the Immunogenicity Analysis Set with available data were analyzed. The Immunogenicity Analysis Set included all participants who received any amount of magrolimab and have at least 1 evaluable anti-magrolimab antibody test result.
Posted
Number
percentage of participants
Up to end of treatment (up to approximately 73 weeks)
Participants received magrolimab + pembrolizumab + platinum + 5 FU (5-fluorouracil) intravenous (IV) infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 73 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 73 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18.3 weeks (for carboplatin).
Participants received magrolimab + pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 72 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 88 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 22 weeks for carboplatin and 23 weeks for cisplatin.
Secondary
Phase 2 Cohort 1, Arms B and C: Progression-free Survival (PFS)
PFS was defined as the time from the date of randomization (Phase 2 Cohorts 1) or date of dose initiation (Phase 2 Cohorts 2 and 3) until the earliest date of documented disease progression as determined by investigator assessment per RECIST, version 1.1, or death from any cause, whichever occurs first. Disease progression is defined in OM#2. KM estimates were used in outcome measure analysis.
Participants in Phase 2 Cohort 1 Arms B and C in the ITT Analysis Set were analyzed.
Participants received pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 70 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks for carboplatin and 18 weeks for cisplatin.
Participants received magrolimab + zimberelimab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 37 weeks; Zimberelimab 360 mg IV on Day 1 of every 21-day cycle for up to 40 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18 weeks for carboplatin and 16 weeks for cisplatin.
Secondary
Phase 2 Cohort 1, Arms A, B and C: Objective Response Rate (ORR)
ORR was defined as the percentage of participants who achieved a CR or PR as determined by investigator assessment. CR and PR are defined in OM#3.
Participants in Phase 2 Cohort 1, Arms A, B and C in the ITT Analysis Set were analyzed.
Participants received magrolimab + pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 72 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 88 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 22 weeks for carboplatin and 23 weeks for cisplatin.
Participants received pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 70 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks for carboplatin and 18 weeks for cisplatin.
Secondary
Phase 2 Cohort 3: Progression-free Survival (PFS)
PFS was defined as the time from the date of dose initiation (Phase 2 Cohort 3) until the earliest date of documented disease progression as determined by investigator assessment per RECIST, version 1.1, or death from any cause, whichever occurs first. Disease progression is defined in OM#2. KM estimates were used in outcome measure analysis
Participants in Phase 2 Cohort 3 in the mITT Analysis Set were analyzed.
Posted
Median
95% Confidence Interval
months
Up to 129 weeks
ID
Title
Description
OG000
Phase 2 Cohort 3: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 42 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 34 weeks.
Units
Counts
Participants
OG000
Secondary
All Phase 2 Cohorts: Duration of Response (DOR)
DOR was defined as the time from first documentation of CR or PR to the earliest date of documented disease progression or death from any cause, whichever occurs first. Disease progression is defined in OM#2 and CR and PR are defined in OM#3.
Participants in Phase 2 Cohort 1, Arms A, B and C in the ITT and participants in Phase 2 Cohort 3 in the mITT analysis set who achieved overall response were analyzed.
Participants received magrolimab + pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 72 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 88 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 22 weeks for carboplatin and 23 weeks for cisplatin.
Participants received pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 70 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks for carboplatin and 18 weeks for cisplatin.
Secondary
All Phase 2 Cohorts: Overall Survival (OS)
OS was defined as the time from the date of randomization (Phase 2 Cohorts 1) or time from the date of dose initiation (Phase 2) to death from any cause. KM estimates were used in outcome measure analysis.
Participants in Phase 2 Cohort 1, Arms A, B and C in the ITT and participants in Phase 2 Cohort 3 in the mITT analysis set were analyzed.
Participants received magrolimab + pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 72 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 88 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 22 weeks for carboplatin and 23 weeks for cisplatin.
Participants received pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 70 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks for carboplatin and 18 weeks for cisplatin.
Secondary
Phase 2 Cohorts: Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) Score
EORTC QLQ-C30 is a quality of life (QOL) questionnaire for cancer participants, that has 30 items. 5 functional scales (physical, role, emotional, cognitive, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, loss of appetite, constipation, diarrhea, and financial difficulties). Scoring of the QLQ-C30 was performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the participant), while higher scores on the symptom and single-item scales indicated a higher level of symptoms (i.e. a worse state of the participant).
Phase 2 Cohort 1: Participants in the Intent to Treat Analysis Set with available data were analyzed. Phase 2 Cohort 3: Participants in the Modified Intent-to-Treat analysis set with available data were analyzed.
Participants received magrolimab + pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 72 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 88 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 22 weeks for carboplatin and 23 weeks for cisplatin.
Secondary
Phase 2 Cohorts: Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life - Head and Neck Module (EORTC QLQ-H&N35)
The H&N35 is a 35-item questionnaire for participants with H&N cancer. It includes 7 multi-item scales that assess pain (4 items), swallowing (4 items), senses (2 items), speech (3 items), social eating (4 items), social contact (5 items), and sexuality (2 items). There are also 11 single items: teeth, opening mouth, dry mouth, sticky saliva, coughing, felt ill, pain killers, nutritional supplements, feeding tube, weight loss, weight gain. All symptoms scales, scores were transformed in range of 0 to 100, where higher scores indicated more severe symptoms. A negative change from Baseline indicated improvement.
Phase 2 Cohort 1: Participants in the Intent-to-Treat Analysis Set with available data were analyzed. Phase 2 Cohort 3: Participants in the Modified Intent-to-Treat Analysis Set with available data were analyzed.
Participants received magrolimab + pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 72 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 88 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 22 weeks for carboplatin and 23 weeks for cisplatin.
Secondary
Phase 2 Cohorts: Number of Participants With 5-level EuroQol 5 Dimensions Questionnaire (EQ-5D-5L) Score
EQ-5D-5L was an instrument for use as a measure of health outcome. The EQ-5D-5L consisted of 2 sections: EuroQoL (5 dimensions) (EQ-5D) descriptive system and the EuroQoL visual analogue scale (EQ-VAS). EQ-5D comprised the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension had 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Number of participants per category are reported.
Phase 2 Cohort 1: Participants in the Intent-to-Treat Analysis Set with available data were analyzed. Phase 2 Cohort 3: Participants in the Modified Intent-to-Treat Analysis Set with available data were analyzed.
Participants received magrolimab + pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 72 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 88 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 22 weeks for carboplatin and 23 weeks for cisplatin.
Secondary
Phase 2 Cohorts: Change From Baseline in the EuroQol Visual Analogue Scale (EQ-VAS) Score
The EQ-VAS recorded the participant's self-rated health on a vertical VAS, where the end points were labeled "the best health you can imagine" and "the worst health you can imagine." The EQ-VAS could be used as a quantitative measure of a health outcome that reflected the participant's own judgment. The EQ-VAS recorded the participant's self-rated health on a vertical VAS, with a score numbered from 0 to 100, where '100 meant the best health you can imagine' and '0 meant the worst health you can imagine".
Phase 2 Cohort 1: Participants in the Intent-to-Treat Analysis Set with available data were analyzed. Phase 2 Cohort 3: Participants in the Modified Intent-to-Treat Analysis Set with available data were analyzed.
Participants received magrolimab + pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 72 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 88 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 22 weeks for carboplatin and 23 weeks for cisplatin.
Time Frame
All-Cause Mortality: Up to 129 weeks; Adverse Events: Up to 73 weeks plus 30 days
Description
All-cause mortality: All Enrolled Analysis Set included all participants who received a study subject identification number in the study after screening.
Adverse events: The Safety Analysis Set included all participants who took at least 1 dose of any study drug.
Participants received magrolimab + pembrolizumab + platinum + 5 FU (5-fluorouracil) intravenous (IV) infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 73 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 73 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18.3 weeks (for carboplatin).
Participants received magrolimab + pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 72 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 88 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 22 weeks for carboplatin and 23 weeks for cisplatin.
Participants received pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 70 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks for carboplatin and 18 weeks for cisplatin.
Participants received magrolimab + zimberelimab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 37 weeks; Zimberelimab 360 mg IV on Day 1 of every 21-day cycle for up to 40 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18 weeks for carboplatin and 16 weeks for cisplatin.
9
32
15
29
28
29
EG004
Safety Run-in Cohort 2: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 69 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 13 weeks.
6
8
6
7
7
7
EG005
Phase 2 Cohort 3: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 42 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 34 weeks.
24
41
24
41
40
41
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Anaemia
Blood and lymphatic system disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0013 affected52 at risk
EG0020 affected53 at risk
EG0030 affected29 at risk
EG0042 affected7 at risk
EG0054 affected41 at risk
Febrile neutropenia
Blood and lymphatic system disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0012 affected52 at risk
EG0025 affected53 at risk
EG003
Leukopenia
Blood and lymphatic system disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Neutropenia
Blood and lymphatic system disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Pancytopenia
Blood and lymphatic system disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Splenic haemorrhage
Blood and lymphatic system disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Thrombocytopenia
Blood and lymphatic system disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Acute myocardial infarction
Cardiac disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Atrial fibrillation
Cardiac disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0021 affected53 at risk
EG003
Cardiac arrest
Cardiac disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Cardiac tamponade
Cardiac disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Cardio-respiratory arrest
Cardiac disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Myocardial infarction
Cardiac disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Vertigo
Ear and labyrinth disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Hypothyroidism
Endocrine disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Abdominal pain
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Abdominal pain upper
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Aphthous ulcer
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Ascites
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Diarrhoea
Gastrointestinal disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Dysphagia
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Gastric ulcer perforation
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Mouth haemorrhage
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Nausea
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Neutropenic colitis
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Oral cavity fistula
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Stomatitis
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Vomiting
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Catheter site haemorrhage
General disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Fatigue
General disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Hyperthermia
General disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Mucosal inflammation
General disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Pyrexia
General disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0012 affected52 at risk
EG0021 affected53 at risk
EG003
Cholecystitis acute
Hepatobiliary disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Hepatic cytolysis
Hepatobiliary disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Anal abscess
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Bronchitis viral
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Cellulitis staphylococcal
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Covid-19
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Enterocolitis infectious
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Epididymitis
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Erysipelas
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Gastroenteritis cryptosporidial
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Genital herpes simplex
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Hepatic infection
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Localised infection
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Lower respiratory tract infection viral
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Lung abscess
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Oral fungal infection
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Oral infection
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Pharyngeal abscess
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Pneumonia
Infections and infestations
27.0
Systematic Assessment
EG0004 affected6 at risk
EG0011 affected52 at risk
EG0022 affected53 at risk
EG003
Pneumonia aspiration
Infections and infestations
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0011 affected52 at risk
EG0021 affected53 at risk
EG003
Pneumonia bacterial
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Pneumonia necrotising
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Sepsis
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0021 affected53 at risk
EG003
Septic shock
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0022 affected53 at risk
EG003
Staphylococcal sepsis
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Subcutaneous abscess
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Systemic candida
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Tongue abscess
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Tooth infection
Infections and infestations
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Tracheitis
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Urinary tract infection
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Vascular device infection
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Wound infection
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Clavicle fracture
Injury, poisoning and procedural complications
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Craniocerebral injury
Injury, poisoning and procedural complications
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Femur fracture
Injury, poisoning and procedural complications
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Infusion related reaction
Injury, poisoning and procedural complications
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Post procedural haematoma
Injury, poisoning and procedural complications
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Post procedural haemorrhage
Injury, poisoning and procedural complications
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Stoma site discharge
Injury, poisoning and procedural complications
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Wound haemorrhage
Injury, poisoning and procedural complications
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Aspartate aminotransferase increased
Investigations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Platelet count decreased
Investigations
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Dehydration
Metabolism and nutrition disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Hypercalcaemia
Metabolism and nutrition disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0012 affected52 at risk
EG0020 affected53 at risk
EG003
Hyperglycaemia
Metabolism and nutrition disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Type 2 diabetes mellitus
Metabolism and nutrition disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Cancer pain
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Tumour haemorrhage
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Tumour pain
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Middle cerebral artery stroke
Nervous system disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Seizure
Nervous system disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0012 affected52 at risk
EG0020 affected53 at risk
EG003
Syncope
Nervous system disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Anxiety
Psychiatric disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Delirium
Psychiatric disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Disorientation
Psychiatric disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Acute kidney injury
Renal and urinary disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0014 affected52 at risk
EG0021 affected53 at risk
EG003
Nephrolithiasis
Renal and urinary disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Acquired tracheo-oesophageal fistula
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Dyspnoea
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0021 affected53 at risk
EG003
Epistaxis
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Pharyngeal haemorrhage
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Pleural effusion
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Pneumonitis
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Pulmonary embolism
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0022 affected53 at risk
EG003
Skin haemorrhage
Skin and subcutaneous tissue disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Toxic skin eruption
Skin and subcutaneous tissue disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Hypotension
Vascular disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Peripheral embolism
Vascular disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Peripheral ischaemia
Vascular disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Superior vena cava syndrome
Vascular disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Thrombophlebitis
Vascular disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Septic shock from neutropenic colitis
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Anaemia
Blood and lymphatic system disorders
27.0
Systematic Assessment
EG0005 affected6 at risk
EG00143 affected52 at risk
EG00237 affected53 at risk
EG00321 affected29 at risk
EG0045 affected7 at risk
EG00528 affected41 at risk
Febrile neutropenia
Blood and lymphatic system disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0012 affected52 at risk
EG0021 affected53 at risk
EG003
Haemolysis
Blood and lymphatic system disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Leukopenia
Blood and lymphatic system disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0014 affected52 at risk
EG0027 affected53 at risk
EG003
Lymphopenia
Blood and lymphatic system disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0019 affected52 at risk
EG0026 affected53 at risk
EG003
Neutropenia
Blood and lymphatic system disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG00116 affected52 at risk
EG00212 affected53 at risk
EG003
Thrombocytopenia
Blood and lymphatic system disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG00116 affected52 at risk
EG00220 affected53 at risk
EG003
Atrial flutter
Cardiac disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Cardiac failure congestive
Cardiac disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Ventricular hypokinesia
Cardiac disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Ear pain
Ear and labyrinth disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0022 affected53 at risk
EG003
Hypoacusis
Ear and labyrinth disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0013 affected52 at risk
EG0021 affected53 at risk
EG003
Tinnitus
Ear and labyrinth disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0016 affected52 at risk
EG0021 affected53 at risk
EG003
Vertigo
Ear and labyrinth disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0012 affected52 at risk
EG0020 affected53 at risk
EG003
Hypothyroidism
Endocrine disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0013 affected52 at risk
EG0024 affected53 at risk
EG003
Blindness unilateral
Eye disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Vision blurred
Eye disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0021 affected53 at risk
EG003
Abdominal distension
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Abdominal pain
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0021 affected53 at risk
EG003
Abdominal pain upper
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0023 affected53 at risk
EG003
Constipation
Gastrointestinal disorders
27.0
Systematic Assessment
EG0003 affected6 at risk
EG00118 affected52 at risk
EG00216 affected53 at risk
EG003
Diarrhoea
Gastrointestinal disorders
27.0
Systematic Assessment
EG0003 affected6 at risk
EG00111 affected52 at risk
EG00213 affected53 at risk
EG003
Dry mouth
Gastrointestinal disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0012 affected52 at risk
EG0022 affected53 at risk
EG003
Dyspepsia
Gastrointestinal disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0014 affected52 at risk
EG0023 affected53 at risk
EG003
Dysphagia
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0014 affected52 at risk
EG0025 affected53 at risk
EG003
Gastrooesophageal reflux disease
Gastrointestinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0012 affected52 at risk
EG0025 affected53 at risk
EG003
Glossodynia
Gastrointestinal disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Nausea
Gastrointestinal disorders
27.0
Systematic Assessment
EG0004 affected6 at risk
EG00119 affected52 at risk
EG00223 affected53 at risk
EG003
Oral dysaesthesia
Gastrointestinal disorders
27.0
Systematic Assessment
EG0002 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Oral pain
Gastrointestinal disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0011 affected52 at risk
EG0023 affected53 at risk
EG003
Stomatitis
Gastrointestinal disorders
27.0
Systematic Assessment
EG0005 affected6 at risk
EG0017 affected52 at risk
EG00218 affected53 at risk
EG003
Vomiting
Gastrointestinal disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0016 affected52 at risk
EG0027 affected53 at risk
EG003
Asthenia
General disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG00116 affected52 at risk
EG00215 affected53 at risk
EG003
Chills
General disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0013 affected52 at risk
EG0021 affected53 at risk
EG003
Fatigue
General disorders
27.0
Systematic Assessment
EG0005 affected6 at risk
EG00112 affected52 at risk
EG00211 affected53 at risk
EG003
Influenza like illness
General disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0011 affected52 at risk
EG0021 affected53 at risk
EG003
Mucosal inflammation
General disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0015 affected52 at risk
EG0024 affected53 at risk
EG003
Non-cardiac chest pain
General disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Oedema peripheral
General disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0013 affected52 at risk
EG0020 affected53 at risk
EG003
Pain
General disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0014 affected52 at risk
EG0021 affected53 at risk
EG003
Pyrexia
General disorders
27.0
Systematic Assessment
EG0003 affected6 at risk
EG0016 affected52 at risk
EG0023 affected53 at risk
EG003
Bronchitis
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0023 affected53 at risk
EG003
Candida infection
Infections and infestations
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0022 affected53 at risk
EG003
Cellulitis
Infections and infestations
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0011 affected52 at risk
EG0021 affected53 at risk
EG003
Covid-19
Infections and infestations
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0011 affected52 at risk
EG0023 affected53 at risk
EG003
Device related infection
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0021 affected53 at risk
EG003
Ear infection
Infections and infestations
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Furuncle
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Localised infection
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Lower respiratory tract infection
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Nasopharyngitis
Infections and infestations
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0012 affected52 at risk
EG0020 affected53 at risk
EG003
Oral candidiasis
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0012 affected52 at risk
EG0024 affected53 at risk
EG003
Pneumonia
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0012 affected52 at risk
EG0024 affected53 at risk
EG003
Respiratory tract infection
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0012 affected52 at risk
EG0023 affected53 at risk
EG003
Stoma site infection
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0013 affected52 at risk
EG0021 affected53 at risk
EG003
Upper respiratory tract infection
Infections and infestations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0023 affected53 at risk
EG003
Fall
Injury, poisoning and procedural complications
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0021 affected53 at risk
EG003
Infusion related reaction
Injury, poisoning and procedural complications
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0013 affected52 at risk
EG0021 affected53 at risk
EG003
Limb injury
Injury, poisoning and procedural complications
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Stoma site pain
Injury, poisoning and procedural complications
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Alanine aminotransferase increased
Investigations
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0015 affected52 at risk
EG0025 affected53 at risk
EG003
Aspartate aminotransferase increased
Investigations
27.0
Systematic Assessment
EG0002 affected6 at risk
EG0014 affected52 at risk
EG0025 affected53 at risk
EG003
Blood alkaline phosphatase increased
Investigations
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0017 affected52 at risk
EG0022 affected53 at risk
EG003
Blood creatinine increased
Investigations
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0012 affected52 at risk
EG0022 affected53 at risk
EG003
Blood iron decreased
Investigations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Blood thyroid stimulating hormone increased
Investigations
27.0
Systematic Assessment
EG0003 affected6 at risk
EG0014 affected52 at risk
EG0022 affected53 at risk
EG003
C-reactive protein increased
Investigations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Gamma-glutamyltransferase increased
Investigations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0023 affected53 at risk
EG003
Haemoglobin decreased
Investigations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0012 affected52 at risk
EG0023 affected53 at risk
EG003
Lymphocyte count decreased
Investigations
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0016 affected52 at risk
EG0020 affected53 at risk
EG003
Neutrophil count decreased
Investigations
27.0
Systematic Assessment
EG0002 affected6 at risk
EG00111 affected52 at risk
EG0022 affected53 at risk
EG003
Platelet count decreased
Investigations
27.0
Systematic Assessment
EG0005 affected6 at risk
EG0018 affected52 at risk
EG0028 affected53 at risk
EG003
Weight decreased
Investigations
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0013 affected52 at risk
EG0027 affected53 at risk
EG003
White blood cell count decreased
Investigations
27.0
Systematic Assessment
EG0004 affected6 at risk
EG00111 affected52 at risk
EG0024 affected53 at risk
EG003
Decreased appetite
Metabolism and nutrition disorders
27.0
Systematic Assessment
EG0003 affected6 at risk
EG00114 affected52 at risk
EG00210 affected53 at risk
EG003
Dehydration
Metabolism and nutrition disorders
27.0
Systematic Assessment
EG0002 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Failure to thrive
Metabolism and nutrition disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Hypercalcaemia
Metabolism and nutrition disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0015 affected52 at risk
EG0021 affected53 at risk
EG003
Hyperglycaemia
Metabolism and nutrition disorders
27.0
Systematic Assessment
EG0002 affected6 at risk
EG0011 affected52 at risk
EG0021 affected53 at risk
EG003
Hypoalbuminaemia
Metabolism and nutrition disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0013 affected52 at risk
EG0024 affected53 at risk
EG003
Hypocalcaemia
Metabolism and nutrition disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0015 affected52 at risk
EG0022 affected53 at risk
EG003
Hypokalaemia
Metabolism and nutrition disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0017 affected52 at risk
EG00210 affected53 at risk
EG003
Hypomagnesaemia
Metabolism and nutrition disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG00110 affected52 at risk
EG0028 affected53 at risk
EG003
Hyponatraemia
Metabolism and nutrition disorders
27.0
Systematic Assessment
EG0002 affected6 at risk
EG0017 affected52 at risk
EG0029 affected53 at risk
EG003
Hypophosphataemia
Metabolism and nutrition disorders
27.0
Systematic Assessment
EG0003 affected6 at risk
EG0016 affected52 at risk
EG0022 affected53 at risk
EG003
Iron deficiency
Metabolism and nutrition disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Arthralgia
Musculoskeletal and connective tissue disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0012 affected52 at risk
EG0024 affected53 at risk
EG003
Back pain
Musculoskeletal and connective tissue disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0015 affected52 at risk
EG0020 affected53 at risk
EG003
Muscle spasms
Musculoskeletal and connective tissue disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Muscle tightness
Musculoskeletal and connective tissue disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0012 affected52 at risk
EG0020 affected53 at risk
EG003
Musculoskeletal chest pain
Musculoskeletal and connective tissue disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Myalgia
Musculoskeletal and connective tissue disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0012 affected52 at risk
EG0021 affected53 at risk
EG003
Neck pain
Musculoskeletal and connective tissue disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0024 affected53 at risk
EG003
Pain in extremity
Musculoskeletal and connective tissue disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0013 affected52 at risk
EG0020 affected53 at risk
EG003
Pain in jaw
Musculoskeletal and connective tissue disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Cancer pain
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Tumour pain
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Brain fog
Nervous system disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Disturbance in attention
Nervous system disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Dizziness
Nervous system disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0013 affected52 at risk
EG0025 affected53 at risk
EG003
Dysgeusia
Nervous system disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0012 affected52 at risk
EG0021 affected53 at risk
EG003
Headache
Nervous system disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG00110 affected52 at risk
EG0025 affected53 at risk
EG003
Neuropathy peripheral
Nervous system disorders
27.0
Systematic Assessment
EG0003 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Peripheral sensory neuropathy
Nervous system disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0012 affected52 at risk
EG0021 affected53 at risk
EG003
Polyneuropathy
Nervous system disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Presyncope
Nervous system disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0013 affected52 at risk
EG0020 affected53 at risk
EG003
Anxiety
Psychiatric disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0011 affected52 at risk
EG0021 affected53 at risk
EG003
Depression
Psychiatric disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Insomnia
Psychiatric disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0015 affected52 at risk
EG0024 affected53 at risk
EG003
Haematuria
Renal and urinary disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Pollakiuria
Renal and urinary disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0012 affected52 at risk
EG0020 affected53 at risk
EG003
Proteinuria
Renal and urinary disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Cough
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0015 affected52 at risk
EG0027 affected53 at risk
EG003
Dysphonia
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Dyspnoea
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0018 affected52 at risk
EG0026 affected53 at risk
EG003
Dyspnoea exertional
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Haemoptysis
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0011 affected52 at risk
EG0022 affected53 at risk
EG003
Hiccups
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0002 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Increased bronchial secretion
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Laryngeal inflammation
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0014 affected52 at risk
EG0021 affected53 at risk
EG003
Oropharyngeal pain
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0011 affected52 at risk
EG0022 affected53 at risk
EG003
Pleural effusion
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Pneumonitis
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Productive cough
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0012 affected52 at risk
EG0021 affected53 at risk
EG003
Rhinorrhoea
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Tracheal inflammation
Respiratory, thoracic and mediastinal disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Actinic keratosis
Skin and subcutaneous tissue disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Alopecia
Skin and subcutaneous tissue disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0021 affected53 at risk
EG003
Dry skin
Skin and subcutaneous tissue disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0012 affected52 at risk
EG0022 affected53 at risk
EG003
Palmar-plantar erythrodysaesthesia syndrome
Skin and subcutaneous tissue disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0011 affected52 at risk
EG0020 affected53 at risk
EG003
Pruritus
Skin and subcutaneous tissue disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0013 affected52 at risk
EG0022 affected53 at risk
EG003
Rash
Skin and subcutaneous tissue disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0015 affected52 at risk
EG0021 affected53 at risk
EG003
Rash maculo-papular
Skin and subcutaneous tissue disorders
27.0
Systematic Assessment
EG0003 affected6 at risk
EG0014 affected52 at risk
EG0023 affected53 at risk
EG003
Rash pruritic
Skin and subcutaneous tissue disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Skin fissures
Skin and subcutaneous tissue disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0012 affected52 at risk
EG0020 affected53 at risk
EG003
Skin hyperpigmentation
Skin and subcutaneous tissue disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Skin hypopigmentation
Skin and subcutaneous tissue disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Embolism
Vascular disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0010 affected52 at risk
EG0020 affected53 at risk
EG003
Hypertension
Vascular disorders
27.0
Systematic Assessment
EG0001 affected6 at risk
EG0010 affected52 at risk
EG0022 affected53 at risk
EG003
Hypotension
Vascular disorders
27.0
Systematic Assessment
EG0000 affected6 at risk
EG0013 affected52 at risk
EG0023 affected53 at risk
EG003
Certain Agreements
Are all PI(s) employees of the sponsor?
No
Restriction Type
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 69 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 13 weeks.
Participants received pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 70 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks for carboplatin and 18 weeks for cisplatin.
Units
Counts
Participants
OG00052
OG00154
Title
Denominators
Categories
Title
Measurements
OG0005.5(3.0 to 6.9)
OG0015.6(4.2 to 7.4)
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Hazard Ratio (HR)
1.314
2-Sided
95
0.809
2.136
HR along with its 2-sided 95% confidence interval (CI) were estimated using the Cox proportional hazards regression model stratified by the stratification factors at randomization.
Superiority
OG00041
Title
Denominators
Categories
Title
Measurements
OG00012.2(4.1 to 26.2)
Participants received magrolimab + pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 72 weeks; Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 88 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 22 weeks for carboplatin and 23 weeks for cisplatin.
OG002
Safety Run-in Cohort 2: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 69 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 13 weeks.
OG003
Phase 2 Cohort 3: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 42 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 34 weeks.
Participants received pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 70 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks for carboplatin and 18 weeks for cisplatin.
Participants received magrolimab + zimberelimab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 37 weeks; Zimberelimab 360 mg IV on Day 1 of every 21-day cycle for up to 40 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18 weeks for carboplatin and 16 weeks for cisplatin.
OG004
Safety Run-in Cohort 2: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 69 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 13 weeks.
OG005
Phase 2 Cohort 3: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 42 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 34 weeks.
Participants received magrolimab + zimberelimab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 37 weeks; Zimberelimab 360 mg IV on Day 1 of every 21-day cycle for up to 40 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18 weeks for carboplatin and 16 weeks for cisplatin.
Units
Counts
Participants
OG00052
OG00154
OG00232
Title
Denominators
Categories
Title
Measurements
OG00038.5(25.3 to 53.0)
OG00138.9(25.9 to 53.1)
OG00237.5(21.1 to 56.3)
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Odds Ratio (OR)
0.982
2-Sided
95
0.449
2.147
The 2-sided 95% CI is based on Clopper-Pearson method.
Other
OG001
OG002
Odds Ratio (OR)
0.943
2-Sided
95
0.383
2.321
The 2-sided 95% CI is based on Clopper-Pearson method.
Participants received magrolimab + zimberelimab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 37 weeks; Zimberelimab 360 mg IV on Day 1 of every 21-day cycle for up to 40 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18 weeks for carboplatin and 16 weeks for cisplatin.
OG003
Phase 2 Cohort 3: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 42 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 34 weeks.
Units
Counts
Participants
OG00020
OG00121
OG00212
OG0035
Title
Denominators
Categories
Title
Measurements
OG0005.4(3.5 to 9.3)
OG0016.2(3.6 to NA)Upper limit of CI was not estimable due to low number of participants with events.
OG0026.3(2.8 to NA)Upper limit of CI was not estimable due to low number of participants with events.
OG0035.0(3.3 to NA)Upper limit of CI was not estimable due to low number of participants with events.
Participants received magrolimab + zimberelimab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 37 weeks; Zimberelimab 360 mg IV on Day 1 of every 21-day cycle for up to 40 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18 weeks for carboplatin and 16 weeks for cisplatin.
OG003
Phase 2 Cohort 3: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 42 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 34 weeks.
Units
Counts
Participants
OG00052
OG00154
OG00232
OG00341
Title
Denominators
Categories
Title
Measurements
OG00010.8(6.9 to 18.2)
OG00113.3(9.1 to NA)Upper limit of CI was not estimable due to low number of participants with events.
OG002NA(7.9 to NA)Median and upper limit of CI were not estimable due to low number of participants with events.
OG0039.1(6.6 to 12.7)
OG001
Phase 2 Cohort 1 Arm B: Pembrolizumab+ Platinum+5-FU
Participants received pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 70 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks for carboplatin and 18 weeks for cisplatin.
Participants received magrolimab + zimberelimab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 37 weeks; Zimberelimab 360 mg IV on Day 1 of every 21-day cycle for up to 40 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18 weeks for carboplatin and 16 weeks for cisplatin.
OG003
Phase 2 Cohort 3: Magrolimab+Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 42 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 34 weeks.
Units
Counts
Participants
OG00052
OG00150
OG00228
OG00337
Title
Denominators
Categories
Global Health Status / QoL: Baseline
ParticipantsOG00051
ParticipantsOG00150
ParticipantsOG00228
ParticipantsOG00337
Title
Measurements
OG00054.7± 24.9
OG00157.3± 23.2
OG00255.1± 20.8
OG003
Global Health Status / QoL: Change from Baseline at Week 3
ParticipantsOG00042
ParticipantsOG00143
ParticipantsOG00223
ParticipantsOG003
Global Health Status / QoL: Change from Baseline at Week 6
ParticipantsOG00032
ParticipantsOG00136
ParticipantsOG00216
ParticipantsOG003
Global Health Status / QoL: Change from Baseline at Week 9
ParticipantsOG00027
ParticipantsOG00130
ParticipantsOG00218
ParticipantsOG003
Global Health Status / QoL: Change from Baseline at Week 12
ParticipantsOG00031
ParticipantsOG00134
ParticipantsOG00217
ParticipantsOG003
Global Health Status / QoL: Change from Baseline at Week 15
ParticipantsOG00030
ParticipantsOG00129
ParticipantsOG00213
ParticipantsOG003
Global Health Status / QoL: Change from Baseline at Week 18
ParticipantsOG00028
ParticipantsOG00125
ParticipantsOG00211
ParticipantsOG003
Global Health Status / QoL: Change from Baseline at Week 21
ParticipantsOG00023
ParticipantsOG00124
ParticipantsOG00210
ParticipantsOG003
Global Health Status / QoL: Change from Baseline at Week 24
ParticipantsOG00020
ParticipantsOG00118
ParticipantsOG00212
ParticipantsOG003
Global Health Status / QoL: Change from Baseline at Week 27
ParticipantsOG00015
ParticipantsOG00115
ParticipantsOG0026
ParticipantsOG003
Global Health Status / QoL: Change from Baseline at Week 90
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG003
Functional Scales: Physical Functioning: Baseline
ParticipantsOG00052
ParticipantsOG00150
ParticipantsOG00227
ParticipantsOG003
Functional Scales: Physical Functioning: Change from Baseline at Week 3
ParticipantsOG00043
ParticipantsOG00143
ParticipantsOG00222
ParticipantsOG003
Functional Scales: Physical Functioning: Change from Baseline at Week 6
ParticipantsOG00033
ParticipantsOG00136
ParticipantsOG00215
ParticipantsOG003
Functional Scales: Physical Functioning: Change from Baseline at Week 9
ParticipantsOG00028
ParticipantsOG00130
ParticipantsOG00218
ParticipantsOG003
Functional Scales: Physical Functioning: Change from Baseline at Week 12
ParticipantsOG00032
ParticipantsOG00134
ParticipantsOG00216
ParticipantsOG003
Functional Scales: Physical Functioning: Change from Baseline at Week 15
ParticipantsOG00031
ParticipantsOG00129
ParticipantsOG00212
ParticipantsOG003
Functional Scales: Physical Functioning: Change from Baseline at Week 18
ParticipantsOG00029
ParticipantsOG00126
ParticipantsOG00210
ParticipantsOG003
Functional Scales: Physical Functioning: Change from Baseline at Week 21
ParticipantsOG00024
ParticipantsOG00124
ParticipantsOG00211
ParticipantsOG003
Functional Scales: Physical Functioning: Change from Baseline at Week 24
ParticipantsOG00021
ParticipantsOG00117
ParticipantsOG00212
ParticipantsOG003
Functional Scales: Physical Functioning: Change from Baseline at Week 27
ParticipantsOG00016
ParticipantsOG00115
ParticipantsOG0025
ParticipantsOG003
Functional Scales: Physical Functioning: Change from Baseline at Week 90
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG003
Functional Scales: Role Functioning: Baseline
ParticipantsOG00052
ParticipantsOG00149
ParticipantsOG00227
ParticipantsOG00337
Functional Scales: Role Functioning: Change from Baseline at Week 3
ParticipantsOG00043
ParticipantsOG00141
ParticipantsOG00222
ParticipantsOG003
Functional Scales: Role Functioning: Change from Baseline at Week 6
ParticipantsOG00033
ParticipantsOG00135
ParticipantsOG00215
ParticipantsOG003
Functional Scales: Role Functioning: Change from Baseline at Week 9
ParticipantsOG00028
ParticipantsOG00130
ParticipantsOG00218
ParticipantsOG003
Functional Scales: Role Functioning: Change from Baseline at Week 12
ParticipantsOG00032
ParticipantsOG00134
ParticipantsOG00216
ParticipantsOG003
Functional Scales: Role Functioning: Change from Baseline at Week 15
ParticipantsOG00032
ParticipantsOG00129
ParticipantsOG00212
ParticipantsOG003
Functional Scales: Role Functioning: Change from Baseline at Week 18
ParticipantsOG00029
ParticipantsOG00126
ParticipantsOG00210
ParticipantsOG003
Functional Scales: Role Functioning: Change from Baseline at Week 21
ParticipantsOG00024
ParticipantsOG00123
ParticipantsOG00211
ParticipantsOG003
Functional Scales: Role Functioning: Change from Baseline at Week 24
ParticipantsOG00021
ParticipantsOG00118
ParticipantsOG00212
ParticipantsOG003
Functional Scales: Role Functioning: Change from Baseline at Week 27
ParticipantsOG00016
ParticipantsOG00115
ParticipantsOG0025
ParticipantsOG003
Functional Scales: Role Functioning: Change from Baseline at Week 90
Participants received pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 70 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks for carboplatin and 18 weeks for cisplatin.
Participants received magrolimab + zimberelimab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 37 weeks; Zimberelimab 360 mg IV on Day 1 of every 21-day cycle for up to 40 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18 weeks for carboplatin and 16 weeks for cisplatin.
OG003
Phase 2 Cohort 3: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 42 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 34 weeks.
Participants received pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 70 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks for carboplatin and 18 weeks for cisplatin.
Participants received magrolimab + zimberelimab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 37 weeks; Zimberelimab 360 mg IV on Day 1 of every 21-day cycle for up to 40 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18 weeks for carboplatin and 16 weeks for cisplatin.
OG003
Phase 2 Cohort 3: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 42 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 34 weeks.
Participants received pembrolizumab + platinum + 5 FU IV infusions as mentioned below:
Pembrolizumab 200 mg IV on Day 1 of every 21-day cycle for up to 70 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 24 weeks for carboplatin and 18 weeks for cisplatin.
Participants received magrolimab + zimberelimab + platinum + 5 FU IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 37 weeks; Zimberelimab 360 mg IV on Day 1 of every 21-day cycle for up to 40 weeks; 5-FU 1000 mg/m^2/day continuous IV On Day 1 to 4 of Cycles 1 to 6 for 21-day cycle each for up to 19 weeks; Cisplatin 100 mg/m^2 IV or Carboplatin AUC 5 IV on Day 1 of Cycles 1 to 6 for 21-day cycle each for up to 18 weeks for carboplatin and 16 weeks for cisplatin.
OG003
Phase 2 Cohort 3: Magrolimab + Docetaxel
Participants received magrolimab + docetaxel IV infusions as mentioned below:
Magrolimab 1 mg/kg on Cycle 1 Day 1; 30 mg/kg, beginning at Day 8 and for the next 5 doses (Cycle 1 Days 8, 15, and Cycle 2 Days 1, 8 and 15); 60 mg/kg, starting Cycle 3 Day 1 onwards for every 21-day cycle for up to 42 weeks; Docetaxel 75 mg/m^2 IV on Day 1 of every 21-day cycle for up to 34 weeks.
Units
Counts
Participants
OG00052
OG00152
OG00232
OG00341
Title
Denominators
Categories
Baseline
ParticipantsOG00052
ParticipantsOG00150
ParticipantsOG00227
ParticipantsOG00336
Title
Measurements
OG00061.9± 20.96
OG00164.0± 23.15
OG00259.8± 24.86
OG003
Change at Week 3
ParticipantsOG00041
ParticipantsOG00142
ParticipantsOG00223
ParticipantsOG00327
Change at Week 6
ParticipantsOG00030
ParticipantsOG00138
ParticipantsOG00214
ParticipantsOG00326
Change at Week 9
ParticipantsOG00029
ParticipantsOG00129
ParticipantsOG00216
ParticipantsOG00320
Change at Week 12
ParticipantsOG00031
ParticipantsOG00132
ParticipantsOG00216
ParticipantsOG00318
Change at Week 15
ParticipantsOG00031
ParticipantsOG00129
ParticipantsOG00211
ParticipantsOG00318
Change at Week 18
ParticipantsOG00029
ParticipantsOG00125
ParticipantsOG00211
ParticipantsOG00315
Change at Week 21
ParticipantsOG00024
ParticipantsOG00124
ParticipantsOG00211
ParticipantsOG00311
Change at Week 24
ParticipantsOG00021
ParticipantsOG00117
ParticipantsOG00212
ParticipantsOG0037
Change at Week 27
ParticipantsOG00014
ParticipantsOG00113
ParticipantsOG0026
ParticipantsOG0035
Change at Week 90
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
1 affected
29 at risk
EG0043 affected7 at risk
EG0058 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
2 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
3 affected
29 at risk
EG0041 affected7 at risk
EG0056 affected41 at risk
1 affected
29 at risk
EG0041 affected7 at risk
EG0052 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
3 affected
29 at risk
EG0040 affected7 at risk
EG0052 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0052 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
2 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
2 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
4 affected
29 at risk
EG0041 affected7 at risk
EG0052 affected41 at risk
2 affected
29 at risk
EG0040 affected7 at risk
EG0055 affected41 at risk
7 affected
29 at risk
EG0041 affected7 at risk
EG0058 affected41 at risk
5 affected
29 at risk
EG0040 affected7 at risk
EG0054 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
2 affected
29 at risk
EG0040 affected7 at risk
EG0052 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
1 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0052 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
2 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0054 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
4 affected
29 at risk
EG0041 affected7 at risk
EG0057 affected41 at risk
7 affected
29 at risk
EG0042 affected7 at risk
EG00514 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
3 affected
29 at risk
EG0040 affected7 at risk
EG0053 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0055 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0053 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
11 affected
29 at risk
EG0042 affected7 at risk
EG00515 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
3 affected
29 at risk
EG0040 affected7 at risk
EG0052 affected41 at risk
9 affected
29 at risk
EG0042 affected7 at risk
EG00510 affected41 at risk
7 affected
29 at risk
EG0040 affected7 at risk
EG0056 affected41 at risk
10 affected
29 at risk
EG0040 affected7 at risk
EG0057 affected41 at risk
3 affected
29 at risk
EG0041 affected7 at risk
EG0051 affected41 at risk
9 affected
29 at risk
EG0044 affected7 at risk
EG00514 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
3 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
2 affected
29 at risk
EG0041 affected7 at risk
EG0055 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
3 affected
29 at risk
EG0041 affected7 at risk
EG0055 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0051 affected41 at risk
2 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0041 affected7 at risk
EG0052 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0052 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
2 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0052 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0053 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0052 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
2 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0051 affected41 at risk
6 affected
29 at risk
EG0041 affected7 at risk
EG0053 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
3 affected
29 at risk
EG0041 affected7 at risk
EG0054 affected41 at risk
3 affected
29 at risk
EG0040 affected7 at risk
EG0052 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0052 affected41 at risk
4 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
1 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
2 affected
29 at risk
EG0040 affected7 at risk
EG0054 affected41 at risk
4 affected
29 at risk
EG0044 affected7 at risk
EG0059 affected41 at risk
8 affected
29 at risk
EG0043 affected7 at risk
EG0051 affected41 at risk
5 affected
29 at risk
EG0042 affected7 at risk
EG0052 affected41 at risk
4 affected
29 at risk
EG0042 affected7 at risk
EG0058 affected41 at risk
3 affected
29 at risk
EG0043 affected7 at risk
EG00510 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0056 affected41 at risk
4 affected
29 at risk
EG0040 affected7 at risk
EG0055 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0052 affected41 at risk
6 affected
29 at risk
EG0040 affected7 at risk
EG0056 affected41 at risk
8 affected
29 at risk
EG0042 affected7 at risk
EG0054 affected41 at risk
8 affected
29 at risk
EG0041 affected7 at risk
EG0056 affected41 at risk
8 affected
29 at risk
EG0040 affected7 at risk
EG0055 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
4 affected
29 at risk
EG0041 affected7 at risk
EG0052 affected41 at risk
4 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0053 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
2 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0052 affected41 at risk
1 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0051 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0041 affected7 at risk
EG0051 affected41 at risk
3 affected
29 at risk
EG0042 affected7 at risk
EG0052 affected41 at risk
8 affected
29 at risk
EG0042 affected7 at risk
EG0057 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0054 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0052 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0053 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
3 affected
29 at risk
EG0041 affected7 at risk
EG0053 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
5 affected
29 at risk
EG0041 affected7 at risk
EG0055 affected41 at risk
2 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
5 affected
29 at risk
EG0041 affected7 at risk
EG00510 affected41 at risk
0 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0041 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0052 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
1 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
3 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
3 affected
29 at risk
EG0040 affected7 at risk
EG0059 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0053 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0051 affected41 at risk
1 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
2 affected
29 at risk
EG0040 affected7 at risk
EG0050 affected41 at risk
1 affected
29 at risk
EG0041 affected7 at risk
EG0050 affected41 at risk
0 affected
29 at risk
EG0042 affected7 at risk
EG0053 affected41 at risk
459
± 140
Title
Measurements
OG001149± 52.8
OG003125± 49.4
Title
Measurements
OG000208± 185
OG001250± 100
OG002255± 149
OG003253± 110
Title
Measurements
OG000359± 253
OG001397± 195
OG002561± 514
OG003477± 219
Title
Measurements
OG0011440± 306
OG0031330± 426
Title
Measurements
OG003572± NAStandard Deviation cannot be calculated for one participant.
Title
Measurements
OG000138± 106
OG001308± 140
OG002813± 830
OG003272± 119
Title
Measurements
OG000142± 113
OG001204± 235
OG003393± NAStandard Deviation cannot be calculated for one participant.
Title
Measurements
OG000707± NAStandard Deviation cannot be calculated for one participant.
OG001359± 94.9
OG002NA± 0Data is not available as the concentrations were below the level of quantification.
OG003270± 95.9
Title
Measurements
OG002NA± 0Data is not available as the concentrations were below the level of quantification.
Title
Measurements
OG00174.8± NAStandard Deviation cannot be calculated for one participant.
Title
Measurements
OG000543± NAStandard Deviation cannot be calculated for one participant.
OG001252± NAStandard Deviation cannot be calculated for one participant.
Title
Measurements
OG001228± NAStandard Deviation cannot be calculated for one participant.
5.0
Participants
OG004
6
ParticipantsOG00540
Title
Measurements
OG0000
OG0010
OG0033.1
OG0040
OG0053.1
55.4
± 25.6
29
Title
Measurements
OG0005.0± 20.2
OG0011.9± 23.3
OG002-3.6± 16.1
OG0031.7± 18.1
26
Title
Measurements
OG0006.0± 26.5
OG00110.2± 26.7
OG002-1.0± 16.9
OG003-1.3± 23.7
21
Title
Measurements
OG0002.8± 22.2
OG0011.1± 27.6
OG002-4.2± 18.6
OG0032.0± 19.0
18
Title
Measurements
OG000-4.8± 29.2
OG0016.4± 25.8
OG0022.9± 14.1
OG003-4.2± 20.5
18
Title
Measurements
OG000-0.3± 27.0
OG0015.2± 25.8
OG0022.6± 22.7
OG0030.0± 24.8
15
Title
Measurements
OG0005.4± 27.0
OG00110.0± 26.4
OG002-4.5± 23.1
OG003-2.8± 23.7
13
Title
Measurements
OG0004.3± 28.1
OG0014.9± 22.4
OG002-10.8± 23.6
OG003-8.3± 20.7
9
Title
Measurements
OG0009.2± 26.3
OG0011.9± 20.9
OG002-5.6± 23.9
OG003-10.2± 15.5
5
Title
Measurements
OG0002.2± 27.7
OG0010.0± 18.6
OG0026.9± 26.0
OG0031.7± 24.6
0
Title
Measurements
OG00033.3± NAStandard deviation cannot be calculated for one participant.
37
Title
Measurements
OG00075.0± 25.3
OG00175.4± 23.2
OG00274.9± 23.2
OG00373.7± 23.8
29
Title
Measurements
OG000-4.8± 15.6
OG001-3.6± 21.2
OG002-9.2± 15.7
OG003-2.9± 17.0
27
Title
Measurements
OG000-3.4± 14.4
OG0012.2± 20.2
OG002-6.2± 15.6
OG003-11.3± 21.7
21
Title
Measurements
OG000-1.4± 21.3
OG001-1.0± 18.8
OG002-4.3± 15.9
OG003-2.9± 13.9
18
Title
Measurements
OG000-4.5± 22.7
OG0013.8± 23.7
OG002-5.3± 15.7
OG003-10.0± 17.5
18
Title
Measurements
OG000-6.5± 21.0
OG0013.3± 26.2
OG002-13.3± 24.1
OG003-11.9± 19.7
15
Title
Measurements
OG0000.0± 15.5
OG0012.7± 27.7
OG002-4.7± 13.4
OG003-16.0± 20.7
13
Title
Measurements
OG000-5.0± 20.9
OG001-6.5± 21.4
OG002-12.1± 19.3
OG003-21.0± 24.2
9
Title
Measurements
OG000-5.1± 15.9
OG001-7.4± 23.6
OG002-8.3± 14.0
OG003-21.5± 10.9
5
Title
Measurements
OG000-7.9± 17.6
OG0010.0± 20.3
OG002-12.0± 14.5
OG003-22.7± 18.0
0
Title
Measurements
OG0000.0± NAStandard deviation cannot be calculated for one participant.
Title
Measurements
OG00072.8± 32.5
OG00174.5± 27.7
OG00269.8± 32.0
OG00360.8± 35.4
29
Title
Measurements
OG000-1.9± 21.6
OG001-2.4± 33.9
OG002-12.1± 37.2
OG003-5.7± 28.3
26
Title
Measurements
OG000-5.1± 23.4
OG0012.4± 32.6
OG002-10.0± 19.7
OG003-3.2± 26.7
9
Title
Measurements
OG000-3.6± 29.2
OG001-5.6± 35.1
OG002-9.3± 30.4
OG0037.9± 27.2
18
Title
Measurements
OG000-6.2± 35.9
OG0012.0± 38.0
OG002-7.3± 33.3
OG003-8.3± 37.6
18
Title
Measurements
OG000-10.4± 36.4
OG0017.5± 35.8
OG002-6.9± 28.8
OG003-4.6± 32.2
15
Title
Measurements
OG000-4.0± 30.7
OG001-1.3± 37.1
OG002-5.0± 19.3
OG003-7.8± 37.2
13
Title
Measurements
OG000-6.9± 38.0
OG001-11.6± 29.1
OG002-13.6± 35.6
OG003-14.1± 39.0
9
Title
Measurements
OG000-4.8± 32.6
OG001-2.8± 30.9
OG0020.0± 24.6
OG003-20.4± 21.7
5
Title
Measurements
OG000-16.7± 21.1
OG001-11.1± 37.1
OG002-10.0± 22.4
OG003-23.3± 19.0
0
Title
Measurements
OG0000.0± NAStandard deviation cannot be calculated for one participant.
37
Title
Measurements
OG00069.5± 25.3
OG00169.7± 27.6
OG00270.3± 28.3
OG00381.5± 16.4
29
Title
Measurements
OG0007.7± 25.1
OG0017.5± 25.2
OG0025.7± 20.9
OG0031.2± 17.5
26
Title
Measurements
OG00012.6± 23.5
OG00112.3± 25.9
OG0024.0± 24.6
OG003-5.7± 21.8
21
Title
Measurements
OG0007.7± 19.8
OG0016.1± 16.5
OG00211.4± 22.6
OG0030.1± 14.8
18
Title
Measurements
OG0003.8± 24.6
OG00111.8± 20.7
OG0029.6± 21.0
OG0031.5± 11.6
18
Title
Measurements
OG0000.3± 28.0
OG00111.8± 27.1
OG0023.6± 19.8
OG003-5.4± 19.3
15
Title
Measurements
OG0003.7± 23.8
OG00112.0± 25.8
OG0026.6± 28.6
OG003-4.4± 16.5
13
Title
Measurements
OG0000.8± 22.6
OG0012.0± 22.5
OG0026.7± 12.3
OG003-5.6± 12.7
9
Title
Measurements
OG0003.1± 20.0
OG0014.6± 22.4
OG0022.4± 19.8
OG003-4.3± 9.0
5
Title
Measurements
OG0000.6± 16.5
OG0019.6± 10.9
OG0026.5± 27.6
OG003-11.1± 18.1
0
Title
Measurements
OG0000.0± NAStandard deviation cannot be calculated for one participant.
37
Title
Measurements
OG00084.0± 22.1
OG00184.7± 22.3
OG00285.7± 16.8
OG00383.8± 21.3
29
Title
Measurements
OG0001.6± 16.0
OG001-0.4± 20.7
OG002-7.2± 14.1
OG003-4.6± 16.6
26
Title
Measurements
OG0002.1± 15.7
OG0010.9± 25.8
OG002-1.0± 7.4
OG003-2.6± 24.4
21
Title
Measurements
OG0001.9± 14.1
OG001-0.6± 14.8
OG002-2.8± 13.1
OG003-4.8± 19.1
18
Title
Measurements
OG000-6.5± 23.8
OG0011.5± 18.5
OG002-4.9± 12.9
OG003-3.7± 20.3
18
Title
Measurements
OG000-3.8± 22.2
OG0010.6± 19.1
OG002-1.3± 12.7
OG003-1.9± 13.9
15
Title
Measurements
OG000-4.8± 22.2
OG001-1.3± 20.9
OG002-6.1± 8.4
OG003-3.3± 16.9
13
Title
Measurements
OG000-3.6± 20.1
OG001-0.7± 18.7
OG002-6.7± 8.6
OG003-10.3± 26.8
9
Title
Measurements
OG000-3.3± 16.8
OG001-3.7± 18.6
OG002-3.8± 12.1
OG003-13.0± 16.2
5
Title
Measurements
OG0000.0± 15.4
OG001-4.4± 11.7
OG002-5.6± 8.6
OG003-33.3± 31.2
0
Title
Measurements
OG00016.7± NAStandard deviation cannot be calculated for one participant.
37
Title
Measurements
OG00075.5± 26.5
OG00173.8± 31.2
OG00276.8± 24.1
OG00368.0± 36.9
29
Title
Measurements
OG0002.4± 24.6
OG001-3.5± 33.6
OG002-12.3± 23.7
OG003-3.4± 30.3
26
Title
Measurements
OG0003.6± 27.7
OG0016.9± 33.4
OG002-7.3± 18.2
OG0031.3± 35.6
21
Title
Measurements
OG000-3.7± 28.6
OG001-3.3± 23.3
OG002-7.4± 21.6
OG0039.5± 34.0
18
Title
Measurements
OG000-2.2± 30.0
OG0010.5± 31.0
OG002-4.9± 19.3
OG003-7.4± 27.5
18
Title
Measurements
OG000-8.1± 34.1
OG0014.0± 27.7
OG0025.1± 23.0
OG003-2.8± 41.3
15
Title
Measurements
OG0001.2± 22.6
OG0012.7± 19.6
OG002-1.5± 15.7
OG0037.8± 36.1
13
Title
Measurements
OG000-5.8± 30.0
OG001-0.7± 24.3
OG002-11.7± 28.4
OG003-5.1± 41.6
9
Title
Measurements
OG000-0.8± 28.9
OG001-4.6± 32.7
OG002-1.3± 22.0
OG003-22.2± 25.0
5
Title
Measurements
OG000-2.2± 30.8
OG001-5.6± 12.1
OG002-5.6± 13.6
OG003-33.3± 31.2
0
Title
Measurements
OG0000.0± NAStandard deviation cannot be calculated for one participant.
Title
Measurements
OG00037.4± 28.9
OG00138.6± 24.3
OG00240.1± 30.3
OG00342.9± 29.9
29
Title
Measurements
OG0001.7± 19.7
OG0012.5± 20.8
OG0027.2± 26.7
OG0038.0± 25.7
27
Title
Measurements
OG000-2.7± 21.9
OG001-5.4± 27.3
OG0024.2± 27.5
OG00313.2± 28.9
21
Title
Measurements
OG0000.4± 22.5
OG001-0.2± 31.2
OG0023.8± 29.5
OG003-3.2± 26.8
37
Title
Measurements
OG0002.8± 24.1
OG001-4.4± 26.9
OG0022.0± 26.1
OG0038.6± 27.5
18
Title
Measurements
OG0008.6± 28.4
OG001-4.4± 27.5
OG0028.5± 36.6
OG00312.3± 24.7
15
Title
Measurements
OG0004.2± 23.8
OG001-2.6± 25.5
OG0027.1± 36.6
OG00318.5± 31.6
13
Title
Measurements
OG0003.7± 27.3
OG0012.5± 23.9
OG00211.6± 40.2
OG00315.4± 30.6
9
Title
Measurements
OG0004.8± 22.4
OG0010.9± 24.9
OG0027.7± 29.9
OG00329.6± 15.7
5
Title
Measurements
OG0002.1± 17.8
OG0014.8± 27.8
OG0022.2± 25.3
OG00335.6± 24.1
0
Title
Measurements
OG0000.0± NAStandard deviation cannot be calculated for one participant.
37
Title
Measurements
OG0005.6± 16.6
OG0015.7± 12.4
OG0024.8± 11.9
OG0037.7± 15.5
29
Title
Measurements
OG0006.7± 20.2
OG0015.0± 16.5
OG00215.9± 34.3
OG0032.9± 12.7
27
Title
Measurements
OG0001.0± 13.8
OG0012.3± 21.1
OG0022.1± 16.0
OG0030.6± 16.3
21
Title
Measurements
OG0008.6± 25.1
OG0013.9± 20.4
OG0027.9± 25.1
OG0035.6± 21.3
18
Title
Measurements
OG00013.3± 27.5
OG0013.9± 18.8
OG0021.0± 23.9
OG003-1.9± 13.9
18
Title
Measurements
OG0005.9± 21.8
OG0015.7± 22.8
OG0025.1± 12.5
OG0033.7± 18.6
15
Title
Measurements
OG0003.6± 18.9
OG0014.5± 21.9
OG0023.0± 10.1
OG0035.6± 26.5
13
Title
Measurements
OG0007.6± 18.4
OG0016.3± 21.3
OG00211.1± 29.6
OG0037.7± 20.0
9
Title
Measurements
OG0004.8± 12.0
OG0010.0± 9.9
OG0025.1± 12.5
OG003-1.9± 13.0
5
Title
Measurements
OG0002.1± 12.0
OG0014.4± 13.3
OG00213.3± 18.3
OG003-3.3± 18.3
0
Title
Measurements
OG0000.0± NAStandard deviation cannot be calculated for one participant.
Title
Measurements
OG00037.2± 32.1
OG00140.3± 30.9
OG00239.9± 31.5
OG00336.0± 33.2
29
Title
Measurements
OG000-5.8± 27.4
OG001-3.9± 31.0
OG002-2.9± 25.5
OG003-5.7± 27.9
27
Title
Measurements
OG000-12.1± 22.5
OG001-19.9± 36.0
OG002-10.4± 22.7
OG003-3.7± 34.1
21
Title
Measurements
OG000-7.7± 23.8
OG001-13.9± 29.1
OG002-8.8± 28.5
OG003-13.5± 28.2
18
Title
Measurements
OG000-4.7± 28.5
OG001-23.0± 34.6
OG002-13.7± 24.5
OG003-3.7± 31.6
18
Title
Measurements
OG000-2.6± 31.4
OG001-19.0± 36.4
OG0020.0± 30.4
OG003-4.6± 34.2
15
Title
Measurements
OG000-8.0± 22.5
OG001-18.6± 35.4
OG0026.1± 15.4
OG003-2.2± 30.8
13
Title
Measurements
OG000-1.4± 28.6
OG001-10.4± 31.8
OG002-1.4± 35.9
OG003-6.4± 35.7
9
Title
Measurements
OG000-0.8± 22.0
OG001-12.0± 29.6
OG0020.0± 31.2
OG0039.3± 16.9
5
Title
Measurements
OG0009.4± 28.5
OG001-8.9± 39.3
OG0028.3± 17.5
OG00316.7± 39.1
0
Title
Measurements
OG000-16.7± NAStandard deviation cannot be calculated for one participant.
Title
Measurements
OG00017.0± 25.3
OG00115.3± 24.5
OG00222.6± 31.5
OG00324.3± 32.1
29
Title
Measurements
OG0000.8± 20.1
OG0012.3± 28.5
OG0021.4± 18.7
OG0039.2± 23.4
27
Title
Measurements
OG0002.1± 20.6
OG001-1.9± 27.9
OG0026.3± 18.1
OG00313.6± 34.9
21
Title
Measurements
OG0000.0± 22.2
OG00110.0± 34.1
OG002-5.3± 20.1
OG00311.1± 21.9
18
Title
Measurements
OG0003.1± 23.0
OG0015.9± 32.3
OG0023.9± 20.0
OG0030.0± 19.8
18
Title
Measurements
OG00010.8± 29.0
OG0013.4± 32.5
OG0025.1± 26.7
OG00313.0± 25.9
15
Title
Measurements
OG0004.6± 21.3
OG0017.7± 30.3
OG0029.1± 15.6
OG00324.4± 29.5
13
Title
Measurements
OG0005.6± 21.2
OG00116.7± 32.6
OG00211.1± 35.8
OG00320.5± 29.0
9
Title
Measurements
OG0001.6± 22.3
OG0015.6± 32.8
OG0027.7± 24.2
OG00311.1± 28.9
5
Title
Measurements
OG0002.1± 14.8
OG0014.4± 24.8
OG0026.7± 14.9
OG00313.3± 38.0
0
Title
Measurements
OG0000.0± NAStandard deviation cannot be calculated for one participant.
Title
Measurements
OG00039.1± 27.0
OG00134.7± 30.1
OG00234.5± 35.7
OG00334.2± 33.8
29
Title
Measurements
OG000-17.8± 26.6
OG0010.0± 32.5
OG0022.9± 26.4
OG003-2.3± 23.5
26
Title
Measurements
OG000-15.2± 31.3
OG001-11.1± 39.0
OG00214.6± 32.1
OG0031.3± 31.9
21
Title
Measurements
OG000-11.9± 35.4
OG001-20.0± 38.8
OG002-8.8± 21.8
OG003-9.5± 23.9
18
Title
Measurements
OG000-15.6± 40.6
OG001-16.7± 34.1
OG002-7.8± 30.1
OG003-3.7± 25.3
18
Title
Measurements
OG000-11.8± 36.1
OG001-13.8± 33.9
OG002-5.1± 23.0
OG003-7.4± 31.4
15
Title
Measurements
OG000-11.5± 27.1
OG001-7.7± 40.3
OG002-3.0± 37.9
OG0036.7± 28.7
13
Title
Measurements
OG000-2.8± 27.7
OG001-6.9± 42.8
OG002-2.8± 17.2
OG003-2.6± 41.9
9
Title
Measurements
OG000-4.8± 30.3
OG001-11.1± 37.9
OG002-10.3± 34.4
OG00311.1± 33.3
5
Title
Measurements
OG0000.0± 36.5
OG0012.2± 44.5
OG0026.7± 27.9
OG00313.3± 50.6
0
Title
Measurements
OG000-33.3± NAStandard deviation cannot be calculated for one participant.
36
Title
Measurements
OG00029.5± 37.7
OG00120.7± 24.2
OG00229.6± 31.1
OG00332.4± 36.1
28
Title
Measurements
OG0006.2± 29.3
OG0017.0± 27.8
OG00213.6± 33.6
OG0032.4± 33.9
27
Title
Measurements
OG000-5.1± 29.0
OG0010.0± 37.0
OG002-4.2± 16.7
OG003-3.7± 36.2
21
Title
Measurements
OG0003.6± 36.7
OG0012.2± 38.1
OG0021.9± 37.0
OG003-4.8± 33.8
18
Title
Measurements
OG0005.4± 44.8
OG001-1.0± 32.8
OG002-2.1± 22.7
OG0037.4± 50.6
17
Title
Measurements
OG0006.5± 37.9
OG0012.3± 36.7
OG0028.3± 28.9
OG0035.9± 29.4
15
Title
Measurements
OG0001.2± 32.1
OG0012.6± 37.6
OG0023.0± 37.9
OG0030.0± 39.8
13
Title
Measurements
OG0006.9± 42.8
OG0019.7± 39.9
OG00213.9± 38.8
OG0032.6± 39.6
9
Title
Measurements
OG0003.2± 27.7
OG0011.9± 33.3
OG0025.1± 32.9
OG0037.4± 36.4
5
Title
Measurements
OG00014.6± 34.4
OG0014.4± 30.5
OG0026.7± 14.9
OG00313.3± 38.0
0
Title
Measurements
OG0000.0± NAStandard deviation cannot be calculated for one participant.
37
Title
Measurements
OG00023.5± 30.0
OG00127.3± 30.6
OG00225.0± 29.6
OG00321.6± 28.6
29
Title
Measurements
OG0000.8± 23.8
OG001-3.1± 33.2
OG0025.8± 32.8
OG0032.3± 21.7
27
Title
Measurements
OG000-6.3± 33.3
OG001-1.9± 33.8
OG0020.0± 32.2
OG0030.0± 20.7
21
Title
Measurements
OG0003.7± 32.5
OG001-2.2± 38.1
OG002-7.0± 23.8
OG0031.6± 26.8
18
Title
Measurements
OG000-2.2± 36.0
OG001-1.0± 32.3
OG002-2.0± 27.6
OG0033.7± 27.7
18
Title
Measurements
OG000-2.2± 31.0
OG001-2.3± 39.8
OG0020.0± 36.0
OG00311.1± 36.2
15
Title
Measurements
OG000-7.1± 31.9
OG001-3.8± 38.1
OG0020.0± 14.9
OG0036.7± 31.4
13
Title
Measurements
OG000-7.2± 31.7
OG0011.4± 39.9
OG002-8.3± 25.1
OG0035.1± 23.0
9
Title
Measurements
OG000-10.0± 40.6
OG0011.9± 47.8
OG002-5.1± 23.0
OG0030.0± 23.6
5
Title
Measurements
OG000-6.7± 42.2
OG0014.4± 41.5
OG002-6.7± 14.9
OG0030.0± 23.6
0
Title
Measurements
OG000-33.3± NAStandard deviation cannot be calculated for one participant.
Title
Measurements
OG0005.2± 12.2
OG0018.7± 20.0
OG0022.4± 8.7
OG0037.2± 17.8
29
Title
Measurements
OG0004.0± 16.8
OG0010.8± 21.2
OG00210.1± 23.4
OG0035.7± 33.4
26
Title
Measurements
OG0000.0± 14.7
OG001-1.9± 17.7
OG0024.2± 11.4
OG0033.8± 35.7
21
Title
Measurements
OG0006.2± 26.2
OG001-1.1± 22.3
OG0029.3± 25.1
OG003-1.6± 19.7
18
Title
Measurements
OG0004.3± 20.6
OG0010.0± 18.6
OG0025.9± 13.1
OG0037.4± 21.6
18
Title
Measurements
OG0008.9± 26.2
OG001-3.4± 24.1
OG00210.3± 21.0
OG00311.1± 32.3
15
Title
Measurements
OG0000.0± 15.7
OG001-4.0± 20.0
OG0026.1± 13.5
OG00311.1± 24.1
13
Title
Measurements
OG0000.0± 10.1
OG0014.2± 22.7
OG0026.7± 14.1
OG00317.9± 22.0
9
Title
Measurements
OG0001.7± 13.1
OG001-7.4± 18.3
OG00210.3± 21.0
OG00314.8± 37.7
5
Title
Measurements
OG0006.7± 13.8
OG001-4.4± 27.8
OG00211.1± 17.2
OG00313.3± 38.0
0
Title
Measurements
OG0000.0± NAStandard deviation cannot be calculated for one participant.
34
Title
Measurements
OG00016.3± 26.1
OG00122.2± 32.5
OG00217.9± 29.4
OG00314.7± 29.8
26
Title
Measurements
OG000-2.4± 26.9
OG0011.6± 32.9
OG0025.8± 21.7
OG003-2.6± 20.9
24
Title
Measurements
OG000-2.1± 18.8
OG0012.9± 31.7
OG0026.3± 25.0
OG0031.4± 20.8
19
Title
Measurements
OG000-1.2± 29.9
OG0013.4± 25.7
OG002-1.9± 13.9
OG003-7.0± 30.6
16
Title
Measurements
OG0003.2± 32.6
OG0018.1± 28.9
OG0020.0± 16.7
OG0036.3± 32.7
17
Title
Measurements
OG0008.9± 30.2
OG0011.2± 32.1
OG002-5.1± 18.5
OG0030.0± 23.6
13
Title
Measurements
OG0000.0± 24.0
OG0012.8± 16.8
OG002-3.0± 10.1
OG003-5.1± 35.6
11
Title
Measurements
OG0000.0± 22.5
OG0010.0± 28.4
OG002-3.3± 10.5
OG003-3.0± 31.5
7
Title
Measurements
OG0005.0± 12.2
OG0015.9± 21.2
OG0020.0± 13.6
OG00319.0± 32.5
4
Title
Measurements
OG0008.9± 15.3
OG0014.8± 17.8
OG0020.0± 21.1
OG0030.0± 0.0
0
Title
Measurements
OG0000.0± NAStandard deviation cannot be calculated for one participant.
25.0
± 25.4
29
Title
Measurements
OG000-2.8± 27.3
OG0013.0± 22.8
OG0026.0± 15.3
OG003-5.7± 21.9
27
Title
Measurements
OG000-4.7± 22.7
OG001-2.9± 31.8
OG0020.0± 23.6
OG003-4.6± 23.7
21
Title
Measurements
OG000-2.1± 24.5
OG001-3.2± 22.4
OG0022.3± 33.1
OG003-6.0± 29.1
19
Title
Measurements
OG000-5.2± 24.7
OG001-7.9± 29.1
OG002-4.6± 26.5
OG0033.9± 21.2
18
Title
Measurements
OG0002.4± 25.6
OG001-5.7± 30.6
OG002-5.8± 24.9
OG003-7.4± 28.9
14
Title
Measurements
OG000-2.1± 21.7
OG001-10.3± 29.1
OG0026.8± 16.2
OG003-1.2± 15.3
13
Title
Measurements
OG0002.1± 27.6
OG001-1.7± 34.6
OG002-6.8± 19.3
OG003-4.5± 31.1
9
Title
Measurements
OG000-3.6± 21.8
OG001-11.8± 37.6
OG002-4.5± 15.1
OG0032.2± 24.6
5
Title
Measurements
OG000-4.2± 24.7
OG001-10.6± 36.1
OG002-6.9± 24.4
OG0035.0± 22.5
0
Title
Measurements
OG000-58.3± NAThe Standard Deviation can not be calculated for one participant.
36
Title
Measurements
OG00030.1± 33.2
OG00133.6± 34.8
OG00231.0± 26.1
OG00336.3± 31.9
28
Title
Measurements
OG000-4.3± 24.6
OG0012.3± 24.5
OG0024.1± 21.3
OG003-3.4± 20.9
26
Title
Measurements
OG000-9.7± 22.5
OG001-8.3± 29.7
OG002-3.1± 22.1
OG003-7.7± 24.5
21
Title
Measurements
OG000-5.9± 24.0
OG001-6.6± 24.9
OG0020.4± 25.5
OG003-9.0± 31.1
19
Title
Measurements
OG000-6.9± 25.0
OG001-3.3± 21.5
OG002-5.4± 15.9
OG003-3.5± 20.8
18
Title
Measurements
OG000-3.0± 29.2
OG001-0.3± 23.0
OG002-8.3± 19.2
OG003-8.3± 23.7
14
Title
Measurements
OG000-5.1± 28.9
OG0010.0± 32.8
OG002-2.3± 10.6
OG003-3.6± 15.6
13
Title
Measurements
OG000-2.2± 25.0
OG0015.7± 33.3
OG002-3.8± 13.6
OG003-15.0± 29.8
9
Title
Measurements
OG000-3.3± 23.0
OG001-1.0± 18.1
OG002-2.6± 18.4
OG0030.0± 20.4
5
Title
Measurements
OG0005.7± 22.7
OG001-5.6± 21.1
OG002-13.9± 11.4
OG003-1.7± 12.4
0
Title
Measurements
OG0000.0± NAThe Standard Deviation can not be calculated for one participant.
36
Title
Measurements
OG00016.0± 25.8
OG00123.5± 30.6
OG00218.5± 26.2
OG00329.2± 29.4
29
Title
Measurements
OG000-0.4± 21.0
OG001-1.2± 21.3
OG0020.7± 19.8
OG003-4.0± 25.8
27
Title
Measurements
OG000-4.2± 21.2
OG0012.8± 30.5
OG0029.4± 14.9
OG0031.9± 22.3
21
Title
Measurements
OG000-3.6± 21.4
OG0010.6± 22.9
OG0023.5± 28.1
OG0030.8± 18.6
19
Title
Measurements
OG0002.1± 14.5
OG001-2.5± 24.3
OG002-4.9± 28.1
OG0033.5± 27.5
18
Title
Measurements
OG0001.0± 25.4
OG0010.6± 25.0
OG002-2.6± 16.5
OG0033.7± 16.7
14
Title
Measurements
OG0004.2± 27.8
OG001-7.1± 17.1
OG002-1.5± 11.7
OG0036.0± 26.6
13
Title
Measurements
OG0003.5± 26.5
OG0014.9± 31.3
OG0021.5± 13.9
OG003-1.3± 19.8
9
Title
Measurements
OG0002.4± 29.0
OG0013.9± 25.4
OG002-1.3± 12.7
OG003-3.7± 27.4
5
Title
Measurements
OG0008.3± 40.4
OG001-2.2± 17.7
OG002-5.6± 13.6
OG00313.3± 13.9
0
Title
Measurements
OG0000.0± NAThe Standard Deviation can not be calculated for one participant.
36
Title
Measurements
OG00036.2± 32.7
OG00132.1± 31.0
OG00232.1± 27.8
OG00329.3± 30.8
28
Title
Measurements
OG000-6.7± 22.2
OG001-1.1± 19.9
OG0020.5± 19.1
OG0034.2± 26.0
25
Title
Measurements
OG000-11.9± 21.4
OG001-6.3± 29.6
OG002-2.1± 20.8
OG003-1.3± 27.1
20
Title
Measurements
OG000-9.0± 27.9
OG0011.0± 20.6
OG0024.7± 20.7
OG003-1.7± 22.3
18
Title
Measurements
OG000-10.7± 23.5
OG001-7.4± 22.0
OG002-7.2± 21.1
OG0034.3± 19.9
17
Title
Measurements
OG000-3.8± 27.7
OG001-0.6± 22.0
OG002-12.8± 14.9
OG0034.6± 24.9
14
Title
Measurements
OG000-7.0± 24.1
OG001-8.3± 19.2
OG002-4.0± 13.4
OG0035.6± 19.4
12
Title
Measurements
OG000-3.5± 20.7
OG0013.0± 18.9
OG002-5.1± 18.0
OG0036.5± 30.9
8
Title
Measurements
OG000-10.5± 20.1
OG0010.7± 17.3
OG002-7.7± 16.0
OG0034.2± 22.2
4
Title
Measurements
OG000-6.3± 24.2
OG001-1.9± 17.3
OG002-9.3± 14.8
OG00322.2± 24.0
0
Title
Measurements
OG000-22.2± NAThe Standard Deviation can not be calculated for one participant.
36
Title
Measurements
OG00033.8± 32.8
OG00134.2± 28.5
OG00228.3± 26.7
OG00324.8± 26.7
28
Title
Measurements
OG0000.7± 31.5
OG0010.2± 24.8
OG0027.4± 20.0
OG0033.9± 14.1
26
Title
Measurements
OG000-9.2± 18.0
OG001-6.9± 33.0
OG0023.0± 16.8
OG0032.4± 25.8
21
Title
Measurements
OG000-8.2± 23.9
OG0011.2± 24.4
OG0024.4± 28.8
OG003-3.6± 17.4
19
Title
Measurements
OG000-4.9± 27.5
OG001-9.4± 24.2
OG0022.5± 24.2
OG0036.1± 15.4
18
Title
Measurements
OG000-3.0± 23.3
OG001-1.4± 32.9
OG002-3.4± 22.5
OG0038.3± 20.0
15
Title
Measurements
OG000-9.2± 21.4
OG0010.0± 30.8
OG0023.5± 25.2
OG0036.1± 24.7
13
Title
Measurements
OG000-8.0± 27.7
OG0017.6± 28.7
OG0024.6± 23.8
OG003-3.8± 20.0
9
Title
Measurements
OG000-17.1± 24.0
OG001-1.0± 20.4
OG0021.7± 26.7
OG0039.9± 23.3
5
Title
Measurements
OG000-3.6± 24.8
OG001-1.2± 13.8
OG0020.5± 16.3
OG00320.0± 19.2
0
Title
Measurements
OG000-8.3± NAThe Standard Deviation can not be calculated for one participant.
37
Title
Measurements
OG00021.4± 24.6
OG00121.7± 28.0
OG00215.5± 22.2
OG00313.4± 19.6
29
Title
Measurements
OG000-3.5± 24.4
OG0015.4± 21.6
OG0025.2± 19.9
OG0036.9± 15.0
26
Title
Measurements
OG000-9.2± 13.9
OG001-2.7± 28.1
OG0022.9± 22.4
OG00310.0± 21.5
21
Title
Measurements
OG000-8.0± 17.6
OG0011.4± 18.5
OG0026.8± 24.8
OG003-0.6± 11.7
19
Title
Measurements
OG000-1.7± 18.0
OG001-5.4± 22.4
OG002-2.8± 19.0
OG0032.5± 20.4
18
Title
Measurements
OG0001.4± 28.6
OG001-2.1± 24.0
OG002-5.1± 15.7
OG0037.0± 19.1
15
Title
Measurements
OG000-1.8± 24.6
OG001-1.6± 22.2
OG002-2.4± 18.7
OG0030.4± 15.0
13
Title
Measurements
OG000-1.9± 26.9
OG0019.3± 18.0
OG002-2.2± 20.4
OG0039.2± 23.0
9
Title
Measurements
OG000-5.1± 22.3
OG0012.7± 11.6
OG0020.5± 23.2
OG0035.2± 9.9
5
Title
Measurements
OG000-4.3± 25.8
OG001-0.9± 19.5
OG002-4.4± 15.6
OG00317.3± 28.5
0
Title
Measurements
OG0000.0± NAThe Standard Deviation can not be calculated for one participant.
34
Title
Measurements
OG00034.0± 34.8
OG00138.9± 41.0
OG00230.9± 29.1
OG00340.2± 37.9
26
Title
Measurements
OG0004.3± 23.5
OG0017.4± 37.9
OG0029.5± 38.6
OG0034.5± 23.8
23
Title
Measurements
OG0004.2± 28.9
OG00116.1± 43.3
OG0023.6± 39.9
OG003-3.6± 32.6
19
Title
Measurements
OG0007.1± 42.2
OG0015.1± 39.4
OG00218.7± 43.4
OG0031.8± 31.4
17
Title
Measurements
OG0000.6± 32.2
OG0015.4± 36.3
OG00222.2± 40.7
OG0032.9± 30.2
16
Title
Measurements
OG0009.5± 43.4
OG0019.0± 42.3
OG0022.8± 48.6
OG0032.1± 30.4
12
Title
Measurements
OG000-3.2± 33.7
OG0012.5± 39.5
OG0025.6± 39.1
OG003-5.6± 32.0
11
Title
Measurements
OG000-2.9± 42.8
OG0010.8± 39.2
OG00221.7± 36.9
OG0033.0± 38.6
7
Title
Measurements
OG000-0.9± 23.9
OG0017.7± 47.4
OG00211.7± 27.3
OG003-9.5± 41.8
3
Title
Measurements
OG0009.0± 23.2
OG0016.9± 47.9
OG002-25.0± 50.0
OG003-33.3± 57.7
0
Title
Measurements
OG000-33.3± NAThe Standard Deviation can not be calculated for one participant.
36
Title
Measurements
OG00021.3± 33.5
OG00116.7± 28.8
OG00214.3± 32.0
OG00330.6± 37.7
29
Title
Measurements
OG000-11.4± 36.2
OG001-0.9± 26.3
OG0027.2± 24.5
OG003-11.5± 27.1
27
Title
Measurements
OG000-5.7± 25.3
OG001-8.3± 36.9
OG0022.1± 14.8
OG003-17.3± 33.8
21
Title
Measurements
OG0006.0± 28.8
OG001-2.5± 22.5
OG002-1.8± 36.0
OG003-17.5± 34.3
19
Title
Measurements
OG0006.7± 34.4
OG0011.1± 33.9
OG0025.9± 29.4
OG003-8.8± 38.2
18
Title
Measurements
OG0000.0± 31.6
OG0015.3± 39.3
OG002-12.8± 29.0
OG003-9.3± 35.8
14
Title
Measurements
OG0000.0± 29.2
OG001-1.4± 45.6
OG0020.0± 14.9
OG003-16.7± 36.4
13
Title
Measurements
OG0004.2± 30.0
OG00110.0± 42.0
OG0026.1± 13.5
OG003-5.1± 26.7
9
Title
Measurements
OG0003.3± 37.3
OG0014.8± 43.1
OG0027.7± 20.0
OG003-22.2± 44.1
5
Title
Measurements
OG0002.4± 24.3
OG001-6.1± 13.5
OG0020.0± 21.1
OG003-20.0± 50.6
0
Title
Measurements
OG0000.0± NAThe Standard Deviation can not be calculated for one participant.
37
Title
Measurements
OG00032.7± 40.7
OG00139.6± 41.1
OG00222.6± 32.8
OG00337.8± 41.7
29
Title
Measurements
OG000-2.4± 34.5
OG0013.3± 30.6
OG00211.6± 21.6
OG003-4.6± 19.4
27
Title
Measurements
OG000-6.5± 33.8
OG001-11.8± 24.5
OG00210.4± 26.4
OG003-6.2± 29.3
21
Title
Measurements
OG0002.5± 34.5
OG001-6.2± 32.1
OG0028.8± 36.6
OG003-4.8± 24.2
19
Title
Measurements
OG000-3.3± 35.4
OG001-9.4± 39.0
OG00211.8± 23.4
OG0030.0± 24.8
18
Title
Measurements
OG0000.0± 38.5
OG001-8.6± 45.8
OG0027.7± 14.6
OG0031.9± 35.2
14
Title
Measurements
OG0003.6± 26.2
OG001-6.7± 36.0
OG00212.1± 16.8
OG0032.4± 27.6
13
Title
Measurements
OG0002.9± 26.4
OG0011.4± 38.2
OG0023.0± 10.1
OG0030.0± 27.2
9
Title
Measurements
OG00010.0± 28.8
OG001-2.1± 39.4
OG00210.3± 21.0
OG003-3.7± 20.0
5
Title
Measurements
OG0008.9± 23.5
OG001-16.7± 31.4
OG0025.6± 13.6
OG00320.0± 29.8
0
Title
Measurements
OG0000.0± NAThe Standard Deviation can not be calculated for one participant.
37
Title
Measurements
OG00042.3± 35.6
OG00138.1± 36.0
OG00234.5± 33.3
OG00349.5± 37.4
29
Title
Measurements
OG000-9.5± 36.3
OG001-0.8± 26.0
OG0020.0± 24.6
OG003-12.6± 32.6
27
Title
Measurements
OG000-9.4± 30.8
OG0010.9± 34.3
OG0022.1± 33.3
OG003-13.6± 29.6
21
Title
Measurements
OG000-7.1± 43.8
OG001-2.3± 28.1
OG0021.8± 32.3
OG003-9.5± 39.6
19
Title
Measurements
OG000-3.1± 37.3
OG001-5.1± 40.9
OG002-3.9± 33.1
OG003-7.0± 17.8
18
Title
Measurements
OG000-5.4± 40.5
OG001-1.2± 41.1
OG0022.6± 37.2
OG003-1.9± 31.3
14
Title
Measurements
OG000-8.3± 35.3
OG001-2.6± 38.8
OG0026.1± 46.7
OG003-11.9± 21.1
13
Title
Measurements
OG000-4.2± 37.2
OG0011.4± 44.5
OG002-3.0± 48.2
OG003-15.4± 29.2
9
Title
Measurements
OG000-4.8± 38.4
OG001-11.8± 37.2
OG002-10.3± 37.0
OG003-14.8± 29.4
5
Title
Measurements
OG0000.0± 42.2
OG001-20.0± 32.9
OG0020.0± 51.6
OG0036.7± 36.5
0
Title
Measurements
OG0000.0± NAThe Standard Deviation can not be calculated for one participant.
36
Title
Measurements
OG00041.0± 35.9
OG00144.9± 36.4
OG00238.1± 36.0
OG00345.4± 41.5
28
Title
Measurements
OG000-7.1± 35.7
OG001-5.6± 36.0
OG0021.4± 40.8
OG003-1.2± 27.9
27
Title
Measurements
OG000-7.3± 23.5
OG001-8.3± 38.5
OG0020.0± 29.8
OG003-1.2± 25.3
21
Title
Measurements
OG000-1.2± 38.7
OG001-10.3± 29.7
OG002-10.5± 35.2
OG0033.2± 36.4
19
Title
Measurements
OG000-1.0± 35.4
OG001-10.1± 30.6
OG002-15.7± 41.0
OG0037.0± 23.8
18
Title
Measurements
OG000-1.0± 26.1
OG001-11.9± 39.8
OG002-11.1± 35.8
OG0030.0± 30.2
14
Title
Measurements
OG000-3.6± 33.1
OG001-10.3± 33.7
OG002-12.1± 45.4
OG0032.4± 27.6
13
Title
Measurements
OG0001.4± 31.8
OG001-12.5± 40.3
OG002-6.1± 41.7
OG0035.1± 42.7
9
Title
Measurements
OG000-3.2± 29.6
OG001-13.7± 33.5
OG002-7.7± 45.4
OG0033.7± 20.0
5
Title
Measurements
OG0000.0± 24.3
OG001-26.7± 22.5
OG002-5.6± 49.1
OG00320.0± 29.8
0
Title
Measurements
OG0000.0± NAThe Standard Deviation can not be calculated for one participant.
37
Title
Measurements
OG00031.4± 28.3
OG00132.7± 35.7
OG00241.7± 33.5
OG00336.9± 30.2
29
Title
Measurements
OG0000.0± 27.5
OG0010.0± 26.9
OG0022.9± 22.3
OG0030.0± 34.5
27
Title
Measurements
OG0000.0± 25.4
OG001-4.6± 40.0
OG002-6.3± 21.8
OG0031.2± 31.3
21
Title
Measurements
OG0003.6± 35.5
OG0010.0± 33.3
OG002-1.8± 28.3
OG003-1.6± 24.7
19
Title
Measurements
OG000-5.2± 26.9
OG001-1.0± 38.6
OG002-7.8± 36.4
OG0038.8± 31.1
18
Title
Measurements
OG0004.3± 30.7
OG001-3.6± 38.9
OG002-2.6± 34.6
OG003-9.3± 25.1
14
Title
Measurements
OG000-4.8± 31.1
OG0012.6± 37.6
OG0020.0± 21.1
OG0037.1± 26.7
13
Title
Measurements
OG000-1.4± 20.8
OG0014.2± 31.6
OG002-6.1± 25.0
OG0032.6± 34.6
9
Title
Measurements
OG000-1.6± 28.8
OG0010.0± 16.7
OG002-17.9± 29.2
OG0033.7± 26.1
5
Title
Measurements
OG000-2.1± 25.7
OG001-6.7± 36.1
OG0020.0± 21.1
OG00313.3± 38.0
0
Title
Measurements
OG0000.0± NAThe Standard Deviation can not be calculated for one participant.
37
Title
Measurements
OG00024.4± 31.0
OG00131.9± 35.4
OG00227.4± 27.3
OG00322.5± 28.4
29
Title
Measurements
OG0001.6± 30.3
OG001-2.4± 28.3
OG00211.6± 25.8
OG0035.7± 28.3
27
Title
Measurements
OG000-8.3± 29.3
OG001-13.0± 36.8
OG0022.1± 19.1
OG003-1.2± 29.9
21
Title
Measurements
OG0004.9± 30.2
OG001-10.7± 39.6
OG002-3.7± 22.5
OG0030.0± 23.6
19
Title
Measurements
OG0001.0± 28.7
OG001-9.4± 31.9
OG002-2.0± 30.0
OG003-1.8± 28.3
18
Title
Measurements
OG0005.4± 31.1
OG001-15.5± 36.8
OG0022.6± 28.7
OG0035.6± 34.8
14
Title
Measurements
OG0003.6± 24.6
OG001-10.7± 36.9
OG0029.1± 15.6
OG0030.0± 29.2
13
Title
Measurements
OG0004.2± 17.9
OG0015.6± 32.1
OG00212.1± 27.0
OG00310.3± 41.7
9
Title
Measurements
OG0003.2± 20.8
OG001-2.0± 27.6
OG0027.7± 20.0
OG00311.1± 37.3
5
Title
Measurements
OG00010.4± 31.5
OG001-4.4± 27.8
OG0025.6± 13.6
OG003-13.3± 38.0
0
Title
Measurements
OG0000.0± NAThe Standard Deviation can not be calculated for one participant.
37
Title
Measurements
OG00078.4± 41.5
OG00175.5± 43.4
OG00278.6± 41.8
OG00378.4± 41.7
28
Title
Measurements
OG0007.3± 34.6
OG0017.1± 46.3
OG0020.0± 52.2
OG0033.6± 42.9
26
Title
Measurements
OG000-12.9± 42.8
OG001-8.3± 55.4
OG0026.3± 68.0
OG003-11.5± 58.8
21
Title
Measurements
OG000-14.8± 45.6
OG0013.4± 32.5
OG002-10.5± 56.7
OG003-14.3± 47.8
19
Title
Measurements
OG000-20.0± 48.4
OG001-9.1± 52.2
OG002-17.6± 52.9
OG0030.0± 33.3
18
Title
Measurements
OG000-16.7± 64.8
OG001-7.1± 46.6
OG002-30.8± 75.1
OG003-11.1± 47.1
15
Title
Measurements
OG000-21.4± 63.0
OG001-4.0± 45.5
OG0020.0± 77.5
OG003-13.3± 51.6
13
Title
Measurements
OG000-30.4± 63.5
OG001-12.5± 53.7
OG002-33.3± 65.1
OG003-15.4± 37.6
9
Title
Measurements
OG000-30.0± 57.1
OG001-25.0± 44.7
OG002-23.1± 59.9
OG003-22.2± 44.1
5
Title
Measurements
OG000-35.7± 63.3
OG001-13.3± 51.6
OG002-33.3± 51.6
OG003-20.0± 44.7
0
Title
Measurements
OG000-100.0± NAThe Standard Deviation can not be calculated for one participant.
37
Title
Measurements
OG00034.0± 47.9
OG00147.9± 50.5
OG00242.9± 50.4
OG00348.6± 50.7
29
Title
Measurements
OG0004.9± 44.4
OG00112.2± 51.0
OG00213.0± 45.8
OG0030.0± 53.5
25
Title
Measurements
OG000-9.7± 53.9
OG001-5.6± 58.3
OG0026.3± 57.4
OG003-12.0± 52.6
20
Title
Measurements
OG0003.7± 64.9
OG001-7.1± 66.3
OG0020.0± 57.7
OG0035.0± 60.5
19
Title
Measurements
OG00017.2± 65.8
OG001-6.3± 56.4
OG0020.0± 50.0
OG003-15.8± 50.1
18
Title
Measurements
OG0003.3± 61.5
OG001-3.7± 58.7
OG002-15.4± 55.5
OG003-11.1± 47.1
15
Title
Measurements
OG000-7.1± 60.4
OG001-4.2± 62.4
OG0020.0± 44.7
OG0036.7± 59.4
13
Title
Measurements
OG0004.3± 63.8
OG0014.3± 63.8
OG00216.7± 57.7
OG00323.1± 59.9
9
Title
Measurements
OG00015.0± 48.9
OG00111.8± 69.7
OG002-15.4± 55.5
OG003-11.1± 60.1
5
Title
Measurements
OG00014.3± 36.3
OG0017.1± 82.9
OG002-16.7± 40.8
OG0030.0± 70.7
0
Title
Measurements
OG0000.0± NAThe Standard Deviation can not be calculated for one participant.
37
Title
Measurements
OG00028.0± 45.4
OG00127.1± 44.9
OG00228.6± 46.0
OG00332.4± 47.5
29
Title
Measurements
OG0004.9± 38.4
OG0014.9± 21.8
OG0024.3± 20.9
OG003-6.9± 25.8
26
Title
Measurements
OG0000.0± 25.8
OG001-5.7± 33.8
OG002-6.7± 25.8
OG003-7.7± 39.2
21
Title
Measurements
OG000-11.1± 32.0
OG0017.1± 26.2
OG0025.3± 40.5
OG003-4.8± 38.4
19
Title
Measurements
OG000-3.4± 32.5
OG0016.1± 34.8
OG002-5.9± 42.9
OG0030.0± 33.3
18
Title
Measurements
OG0003.3± 32.0
OG0010.0± 27.7
OG002-7.7± 49.4
OG0035.6± 23.6
15
Title
Measurements
OG000-3.6± 33.1
OG0014.3± 20.9
OG002-9.1± 30.2
OG0030.0± 37.8
13
Title
Measurements
OG000-4.3± 36.7
OG0014.3± 20.9
OG002-16.7± 38.9
OG0037.7± 27.7
9
Title
Measurements
OG0000.0± 32.4
OG0015.9± 24.3
OG002-15.4± 37.6
OG0030.0± 0.0
5
Title
Measurements
OG0000.0± 0.0
OG0017.7± 27.7
OG002-16.7± 40.8
OG0030.0± 0.0
0
Title
Measurements
OG0000.0± NAThe Standard Deviation can not be calculated for one participant.
37
Title
Measurements
OG00032.0± 47.1
OG00144.9± 50.3
OG00228.6± 46.0
OG00329.7± 46.3
29
Title
Measurements
OG00023.1± 62.7
OG001-4.9± 59.0
OG00230.4± 55.9
OG00310.3± 61.8
26
Title
Measurements
OG000-6.7± 74.0
OG001-13.9± 59.3
OG00212.5± 50.0
OG00319.2± 63.4
21
Title
Measurements
OG0003.7± 70.6
OG001-17.2± 60.2
OG0020.0± 57.7
OG003-9.5± 53.9
19
Title
Measurements
OG000-17.2± 46.8
OG001-18.2± 58.4
OG00211.8± 33.2
OG003-5.3± 52.4
17
Title
Measurements
OG00013.3± 73.0
OG001-10.7± 73.7
OG00215.4± 37.6
OG003-5.9± 65.9
15
Title
Measurements
OG0000.0± 60.9
OG001-20.0± 57.7
OG0020.0± 44.7
OG0036.7± 59.4
13
Title
Measurements
OG0004.3± 47.5
OG001-4.2± 75.1
OG00225.0± 45.2
OG0037.7± 76.0
9
Title
Measurements
OG000-5.0± 39.4
OG001-5.9± 65.9
OG0027.7± 49.4
OG00333.3± 50.0
5
Title
Measurements
OG0000.0± 55.5
OG001-13.3± 74.3
OG0020.0± 0.0
OG00340.0± 54.8
0
Title
Measurements
OG0000.0± NAThe Standard Deviation can not be calculated for one participant.
37
Title
Measurements
OG00014.3± 35.4
OG0018.2± 27.7
OG00221.4± 41.8
OG00318.9± 39.7
29
Title
Measurements
OG0007.7± 53.2
OG00127.5± 55.4
OG0024.3± 36.7
OG003-6.9± 53.0
26
Title
Measurements
OG00010.0± 54.8
OG00125.0± 43.9
OG0020.0± 63.2
OG0037.7± 48.4
21
Title
Measurements
OG0003.8± 59.9
OG00114.3± 44.8
OG0025.6± 63.9
OG00319.0± 60.2
19
Title
Measurements
OG00014.3± 52.5
OG0016.3± 50.4
OG00223.5± 43.7
OG00326.3± 56.2
18
Title
Measurements
OG0006.7± 58.3
OG00125.0± 64.5
OG0020.0± 40.8
OG00311.1± 47.1
15
Title
Measurements
OG0007.4± 38.5
OG00116.7± 56.5
OG002-18.2± 60.3
OG0036.7± 59.4
13
Title
Measurements
OG00018.2± 39.5
OG0014.2± 55.0
OG0020.0± 73.9
OG00315.4± 68.9
9
Title
Measurements
OG00021.1± 63.1
OG00117.6± 52.9
OG0020.0± 40.8
OG00311.1± 60.1
5
Title
Measurements
OG00028.6± 61.1
OG00133.3± 61.7
OG002-16.7± 40.8
OG00320.0± 44.7
0
Title
Measurements
OG000-100.0± NAThe Standard Deviation can not be calculated for one participant.
18
Slight Problems
OG0009
OG00110
OG0024
OG0037
Moderate Problems
OG0005
OG0017
OG0022
OG0039
Severe Problems
OG0002
OG0011
OG0022
OG0032
Extreme Problems
OG0000
OG0011
OG0020
OG0030
Title
Measurements
No Problems
OG00029
OG00128
OG00213
OG00316
Slight Problems
OG0007
OG00110
OG0025
OG0036
Moderate Problems
OG0004
OG0013
OG0023
OG0035
Severe Problems
OG0002
OG0012
OG0022
OG0032
Extreme Problems
OG0000
OG0010
OG0020
OG0031
Title
Measurements
No Problems
OG00017
OG00128
OG00211
OG00312
Slight Problems
OG0007
OG0019
OG0023
OG0038
Moderate Problems
OG0003
OG0011
OG0022
OG0034
Severe Problems
OG0001
OG0011
OG0020
OG0032
Extreme Problems
OG0002
OG0011
OG0020
OG0031
Title
Measurements
No Problems
OG00019
OG00121
OG00212
OG00312
Slight Problems
OG0005
OG0015
OG0025
OG0034
Moderate Problems
OG0004
OG0012
OG0021
OG0034
Severe Problems
OG0001
OG0011
OG0021
OG0031
Extreme Problems
OG0000
OG0011
OG0020
OG0030
Title
Measurements
No Problems
OG00018
OG00122
OG00212
OG00311
Slight Problems
OG0009
OG0016
OG0024
OG0034
Moderate Problems
OG0002
OG0014
OG0022
OG0033
Severe Problems
OG0001
OG0011
OG0020
OG0030
Extreme Problems
OG0001
OG0011
OG0020
OG0031
Title
Measurements
No Problems
OG00022
OG00117
OG0029
OG0039
Slight Problems
OG0005
OG0017
OG0022
OG0035
Moderate Problems
OG0001
OG0015
OG0020
OG0032
Severe Problems
OG0003
OG0011
OG0021
OG0032
Extreme Problems
OG0000
OG0011
OG0020
OG0030
Title
Measurements
No Problems
OG00019
OG00118
OG00210
OG0035
Slight Problems
OG0005
OG0013
OG0021
OG0037
Moderate Problems
OG0002
OG0011
OG0020
OG0032
Severe Problems
OG0003
OG0012
OG0020
OG0032
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG00015
OG00111
OG0029
OG0032
Slight Problems
OG0006
OG0018
OG0021
OG0036
Moderate Problems
OG0002
OG0013
OG0021
OG0033
Severe Problems
OG0001
OG0010
OG0021
OG0031
Extreme Problems
OG0000
OG0012
OG0021
OG0030
Title
Measurements
No Problems
OG00015
OG0015
OG00211
OG0033
Slight Problems
OG0004
OG0018
OG0020
OG0030
Moderate Problems
OG0001
OG0014
OG0022
OG0034
Severe Problems
OG0001
OG0011
OG0020
OG0031
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG0009
OG0017
OG0025
OG0031
Slight Problems
OG0004
OG0015
OG0021
OG0030
Moderate Problems
OG0002
OG0010
OG0020
OG0033
Severe Problems
OG0000
OG0012
OG0020
OG0031
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG0001
Slight Problems
OG0000
Moderate Problems
OG0000
Severe Problems
OG0000
Extreme Problems
OG0000
Title
Measurements
No Problems
OG00038
OG00138
OG00223
OG00330
Slight Problems
OG0006
OG0018
OG0023
OG0033
Moderate Problems
OG0003
OG0012
OG0020
OG0032
Severe Problems
OG0003
OG0010
OG0021
OG0031
Extreme Problems
OG0000
OG0011
OG0020
OG0030
Title
Measurements
No Problems
OG00031
OG00132
OG00216
OG00321
Slight Problems
OG0005
OG0017
OG0025
OG0035
Moderate Problems
OG0005
OG0014
OG0020
OG0032
Severe Problems
OG0001
OG0010
OG0022
OG0032
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG00025
OG00134
OG00213
OG00319
Slight Problems
OG0003
OG0013
OG0023
OG0036
Moderate Problems
OG0001
OG0011
OG0020
OG0030
Severe Problems
OG0000
OG0012
OG0020
OG0032
Extreme Problems
OG0001
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG00022
OG00124
OG00216
OG00317
Slight Problems
OG0005
OG0014
OG0022
OG0033
Moderate Problems
OG0002
OG0011
OG0020
OG0031
Severe Problems
OG0000
OG0011
OG0021
OG0030
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG00024
OG00127
OG00215
OG00317
Slight Problems
OG0005
OG0013
OG0022
OG0031
Moderate Problems
OG0000
OG0014
OG0021
OG0030
Severe Problems
OG0002
OG0010
OG0020
OG0031
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG00024
OG00125
OG00210
OG00313
Slight Problems
OG0004
OG0014
OG0021
OG0035
Moderate Problems
OG0002
OG0011
OG0021
OG0030
Severe Problems
OG0001
OG0011
OG0020
OG0030
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG00022
OG00121
OG00210
OG00313
Slight Problems
OG0004
OG0012
OG0021
OG0032
Moderate Problems
OG0001
OG0010
OG0020
OG0031
Severe Problems
OG0002
OG0011
OG0020
OG0030
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG00018
OG00117
OG00212
OG0038
Slight Problems
OG0004
OG0015
OG0021
OG0032
Moderate Problems
OG0001
OG0011
OG0020
OG0032
Severe Problems
OG0000
OG0010
OG0020
OG0030
Extreme Problems
OG0001
OG0011
OG0020
OG0030
Title
Measurements
No Problems
OG00017
OG00115
OG00211
OG0036
Slight Problems
OG0002
OG0010
OG0021
OG0030
Moderate Problems
OG0002
OG0012
OG0021
OG0032
Severe Problems
OG0000
OG0011
OG0020
OG0030
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG00012
OG00112
OG0026
OG0033
Slight Problems
OG0001
OG0011
OG0020
OG0031
Moderate Problems
OG0002
OG0010
OG0020
OG0031
Severe Problems
OG0000
OG0011
OG0020
OG0030
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG0001
Slight Problems
OG0000
Moderate Problems
OG0000
Severe Problems
OG0000
Extreme Problems
OG0000
Title
Measurements
No Problems
OG00025
OG00124
OG00214
OG00315
Slight Problems
OG00013
OG00114
OG0029
OG00312
Moderate Problems
OG0008
OG0017
OG0021
OG0033
Severe Problems
OG0004
OG0011
OG0022
OG0032
Extreme Problems
OG0001
OG0013
OG0020
OG0034
Title
Measurements
No Problems
OG00016
OG00119
OG0028
OG00310
Slight Problems
OG00017
OG00115
OG0029
OG00311
Moderate Problems
OG0005
OG0016
OG0024
OG0037
Severe Problems
OG0003
OG0012
OG0021
OG0031
Extreme Problems
OG0001
OG0010
OG0021
OG0031
Title
Measurements
No Problems
OG00016
OG00121
OG0028
OG00312
Slight Problems
OG00010
OG00112
OG0023
OG0034
Moderate Problems
OG0002
OG0015
OG0025
OG0035
Severe Problems
OG0001
OG0011
OG0020
OG0034
Extreme Problems
OG0001
OG0011
OG0020
OG0032
Title
Measurements
No Problems
OG00014
OG00119
OG00210
OG00311
Slight Problems
OG00011
OG0014
OG0023
OG0037
Moderate Problems
OG0004
OG0015
OG0026
OG0031
Severe Problems
OG0000
OG0012
OG0020
OG0032
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG00016
OG00121
OG00213
OG0039
Slight Problems
OG00010
OG0018
OG0023
OG0037
Moderate Problems
OG0001
OG0013
OG0022
OG0032
Severe Problems
OG0002
OG0010
OG0020
OG0031
Extreme Problems
OG0002
OG0011
OG0020
OG0030
Title
Measurements
No Problems
OG00015
OG00115
OG0026
OG0037
Slight Problems
OG0008
OG0018
OG0024
OG0037
Moderate Problems
OG0005
OG0015
OG0022
OG0032
Severe Problems
OG0002
OG0011
OG0020
OG0030
Extreme Problems
OG0000
OG0011
OG0020
OG0032
Title
Measurements
No Problems
OG00018
OG00115
OG0027
OG0035
Slight Problems
OG0006
OG0017
OG0024
OG0038
Moderate Problems
OG0002
OG0012
OG0020
OG0031
Severe Problems
OG0002
OG0010
OG0020
OG0032
Extreme Problems
OG0001
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG00015
OG00111
OG0028
OG0032
Slight Problems
OG0009
OG0019
OG0021
OG0034
Moderate Problems
OG0000
OG0012
OG0022
OG0035
Severe Problems
OG0000
OG0010
OG0021
OG0030
Extreme Problems
OG0000
OG0011
OG0021
OG0031
Title
Measurements
No Problems
OG00012
OG00110
OG0027
OG0032
Slight Problems
OG0005
OG0014
OG0023
OG0032
Moderate Problems
OG0002
OG0011
OG0023
OG0033
Severe Problems
OG0001
OG0012
OG0020
OG0030
Extreme Problems
OG0001
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG0008
OG0018
OG0024
OG0031
Slight Problems
OG0004
OG0013
OG0022
OG0030
Moderate Problems
OG0003
OG0011
OG0020
OG0033
Severe Problems
OG0000
OG0012
OG0020
OG0031
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG0001
Slight Problems
OG0000
Moderate Problems
OG0000
Severe Problems
OG0000
Extreme Problems
OG0000
Title
Measurements
No Problems
OG0009
OG00110
OG0024
OG0037
Slight Problems
OG00019
OG00116
OG0028
OG00312
Moderate Problems
OG00015
OG00115
OG00211
OG00312
Severe Problems
OG0006
OG0018
OG0022
OG0035
Extreme Problems
OG0002
OG0011
OG0022
OG0030
Title
Measurements
No Problems
OG00012
OG00112
OG0025
OG0037
Slight Problems
OG00017
OG00112
OG0025
OG0039
Moderate Problems
OG00010
OG00115
OG0027
OG00310
Severe Problems
OG0003
OG0014
OG0025
OG0034
Extreme Problems
OG0000
OG0010
OG0021
OG0030
Title
Measurements
No Problems
OG00010
OG00116
OG0024
OG0036
Slight Problems
OG00015
OG00110
OG0027
OG00310
Moderate Problems
OG0005
OG00111
OG0024
OG0038
Severe Problems
OG0000
OG0013
OG0021
OG0033
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG00010
OG00110
OG0026
OG0037
Slight Problems
OG0009
OG0019
OG0027
OG0035
Moderate Problems
OG0008
OG0018
OG0025
OG0038
Severe Problems
OG0002
OG0013
OG0021
OG0030
Extreme Problems
OG0000
OG0010
OG0020
OG0031
Title
Measurements
No Problems
OG00011
OG00111
OG00210
OG0036
Slight Problems
OG00011
OG00115
OG0024
OG0034
Moderate Problems
OG0005
OG0016
OG0023
OG0038
Severe Problems
OG0003
OG0011
OG0021
OG0030
Extreme Problems
OG0001
OG0011
OG0020
OG0031
Title
Measurements
No Problems
OG00010
OG00111
OG0024
OG0034
Slight Problems
OG00013
OG0017
OG0025
OG0036
Moderate Problems
OG0005
OG0019
OG0023
OG0038
Severe Problems
OG0003
OG0013
OG0020
OG0030
Extreme Problems
OG0000
OG0011
OG0020
OG0030
Title
Measurements
No Problems
OG00010
OG00111
OG0024
OG0035
Slight Problems
OG00011
OG0018
OG0023
OG0037
Moderate Problems
OG0008
OG0015
OG0024
OG0032
Severe Problems
OG0000
OG0010
OG0020
OG0032
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG0009
OG00111
OG0028
OG0033
Slight Problems
OG0007
OG0014
OG0022
OG0033
Moderate Problems
OG0005
OG0016
OG0023
OG0035
Severe Problems
OG0003
OG0013
OG0020
OG0031
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG0007
OG0017
OG0025
OG0033
Slight Problems
OG0007
OG0014
OG0026
OG0031
Moderate Problems
OG0007
OG0016
OG0021
OG0033
Severe Problems
OG0000
OG0010
OG0020
OG0031
Extreme Problems
OG0000
OG0011
OG0021
OG0030
Title
Measurements
No Problems
OG0009
OG0019
OG0024
OG0031
Slight Problems
OG0001
OG0010
OG0022
OG0031
Moderate Problems
OG0004
OG0012
OG0020
OG0032
Severe Problems
OG0001
OG0013
OG0020
OG0030
Extreme Problems
OG0000
OG0010
OG0020
OG0031
Title
Measurements
No Problems
OG0000
Slight Problems
OG0001
Moderate Problems
OG0000
Severe Problems
OG0000
Extreme Problems
OG0000
Title
Measurements
No Problems
OG00020
OG00121
OG0029
OG00322
Slight Problems
OG00020
OG00115
OG00212
OG0039
Moderate Problems
OG0006
OG0018
OG0025
OG0035
Severe Problems
OG0004
OG0013
OG0021
OG0030
Extreme Problems
OG0001
OG0013
OG0020
OG0030
Title
Measurements
No Problems
OG00021
OG00123
OG0028
OG00316
Slight Problems
OG00015
OG0017
OG00211
OG00310
Moderate Problems
OG0003
OG0019
OG0023
OG0033
Severe Problems
OG0003
OG0014
OG0021
OG0031
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG00016
OG00119
OG0028
OG00313
Slight Problems
OG00013
OG00110
OG0025
OG0038
Moderate Problems
OG0001
OG0017
OG0023
OG0035
Severe Problems
OG0000
OG0013
OG0020
OG0031
Extreme Problems
OG0000
OG0011
OG0020
OG0030
Title
Measurements
No Problems
OG0008
OG00118
OG0028
OG00311
Slight Problems
OG00015
OG0018
OG0029
OG0038
Moderate Problems
OG0006
OG0013
OG0022
OG0032
Severe Problems
OG0000
OG0010
OG0020
OG0030
Extreme Problems
OG0000
OG0011
OG0020
OG0030
Title
Measurements
No Problems
OG00014
OG00115
OG0029
OG0039
Slight Problems
OG00014
OG00115
OG0029
OG0039
Moderate Problems
OG0000
OG0014
OG0020
OG0031
Severe Problems
OG0001
OG0010
OG0020
OG0030
Extreme Problems
OG0002
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG00015
OG00114
OG0026
OG00310
Slight Problems
OG00011
OG0016
OG0025
OG0034
Moderate Problems
OG0003
OG0018
OG0021
OG0034
Severe Problems
OG0001
OG0013
OG0020
OG0030
Extreme Problems
OG0001
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG00014
OG00113
OG0024
OG00310
Slight Problems
OG0009
OG0016
OG0025
OG0032
Moderate Problems
OG0004
OG0015
OG0021
OG0033
Severe Problems
OG0002
OG0010
OG0020
OG0030
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG00012
OG00112
OG0028
OG0032
Slight Problems
OG0007
OG0014
OG0024
OG0036
Moderate Problems
OG0004
OG0017
OG0021
OG0034
Severe Problems
OG0000
OG0011
OG0020
OG0030
Extreme Problems
OG0001
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG00010
OG00110
OG0028
OG0033
Slight Problems
OG0008
OG0013
OG0025
OG0032
Moderate Problems
OG0002
OG0014
OG0020
OG0033
Severe Problems
OG0001
OG0011
OG0020
OG0030
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG0007
OG0017
OG0024
OG0031
Slight Problems
OG0004
OG0014
OG0022
OG0031
Moderate Problems
OG0003
OG0011
OG0020
OG0033
Severe Problems
OG0001
OG0012
OG0020
OG0030
Extreme Problems
OG0000
OG0010
OG0020
OG0030
Title
Measurements
No Problems
OG0001
Slight Problems
OG0000
Moderate Problems
OG0000
Severe Problems
OG0000
Extreme Problems
OG0000
62.0
± 22.21
Title
Measurements
OG000-3.7± 20.80
OG0014.3± 20.72
OG0024.1± 17.88
OG003-0.3± 16.20
Title
Measurements
OG0002.2± 14.82
OG0015.7± 24.75
OG0021.1± 15.71
OG003-2.1± 16.37
Title
Measurements
OG000-1.0± 18.19
OG0012.5± 16.89
OG0026.6± 18.50
OG0034.4± 20.74
Title
Measurements
OG0004.5± 18.65
OG0017.9± 23.02
OG0025.9± 19.60
OG003-4.5± 14.55
Title
Measurements
OG0000.1± 18.79
OG00110.5± 23.60
OG0023.2± 15.05
OG003-1.1± 12.86
Title
Measurements
OG000-1.2± 19.34
OG0017.4± 23.33
OG0023.8± 20.11
OG003-8.1± 17.77
Title
Measurements
OG0000.5± 18.59
OG0011.1± 21.12
OG0024.0± 20.15
OG003-8.5± 16.71
Title
Measurements
OG0000.2± 22.05
OG0016.0± 22.45
OG0022.1± 20.72
OG003-13.9± 19.17
Title
Measurements
OG000-10.0± 19.32
OG001-0.9± 22.46
OG00210.0± 21.45
OG003-9.0± 23.56
Title
Measurements
OG00025.0± NAStandard Deviation can not be estimated for one participant.